HK1237266B - Heteroaryl compounds useful as inhibitors of sumo activating enzyme - Google Patents
Heteroaryl compounds useful as inhibitors of sumo activating enzyme Download PDFInfo
- Publication number
- HK1237266B HK1237266B HK17111196.0A HK17111196A HK1237266B HK 1237266 B HK1237266 B HK 1237266B HK 17111196 A HK17111196 A HK 17111196A HK 1237266 B HK1237266 B HK 1237266B
- Authority
- HK
- Hong Kong
- Prior art keywords
- methyl
- mmol
- thienyl
- amino
- chemical entity
- Prior art date
Links
Description
Small ubiquitin-like modifier (SUMO) is a member of the ubiquitin-like protein (Ubl) family that is covalently conjugated to cellular proteins in a manner similar to Ub-conjugation (Kerscher, O., Felberbaum, R., and Hochstrasser, M. 2006. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol. 22:159-80). Mammalian cells express three major isoforms: SUMO1, SUMO2 and SUMO3. SUMO2 and SUMO3 share ∼95% amino acid sequence homology but have ∼45% sequence homology with SUMO1 (Kamitani, T., Kito, K., Nguyen, H. P., Fukuda-Kamitani, T., and Yeh, E. T. 1998. Characterization of a second member of the sentrin family of ubiquitin-like proteins. J Biol Chem. 273(18):11349-53). SUMO proteins can be conjugated to a single lysine residue of a protein (monosumoylation) or to a second SUMO protein that is already conjugated to a protein forming a SUMO chain (polysumoylation). Only SUMO2/3 can form such chains because they possess internal consensus SUMO modification sites (Tatham, M. H., Jaffray, E., Vaughan, O. A., Desterro, J. M., Botting, C. H., Naismith, J. H., Hay, R. T. 2001. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J Biol Chem. 276(38):35368-74). An additional isoform, SUMO4, is found in kidney, lymph node and spleen cells, but it is not known whether SUMO4 can be conjugated to cellular proteins.
SUMO1, SUMO2 and SUMO3 are activated in an ATP-dependent manner by the SUMO-activating enzyme (SAE). SAE is a heterodimer that consists of SAE1 (SUMO-activating enzyme subunit 1) and SAE2 (UBA2). SAE, like other E1 activating enzymes, uses ATP to adenylate the C-terminal glycine residue of SUMO. In a second step, a thioester intermediate is then formed between the C-terminal glycine of SUMO and a cysteine residue in SAE2. Next, SUMO is transferred from the E1 to the cysteine residue of the SUMO conjugating enzyme (E2), UBC9. Unlike the Ub pathway that contains many E2 enzymes, Ubc9 is currently the only known conjugating enzyme for SUMO and functions with SUMO1, SUMO2 and SUMO3 proteins. SUMO proteins are then conjugated to the target protein, either directly or in conjunction with an E3 ligase, through isopeptide bond formation with the epsilon amino group of a lysine side chain on a target protein. Several SUMO E3 ligases, including PIAS (protein inhibitor of activated signal transducer and activator of transcription protein) proteins and Ran-binding protein 2 (RanBP2), and polycomb 2 (Pc2), have been identified (Johnson, E. S., and Gupta, A. A. 2001. An E3-like factor that promotes SUMO conjugation to the yeast septins. Cell. 106(6):735-44; Pichler, A., Gast, A., Seeler, J. S., Dejean, A.; Melchior, F. 2002. The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell. 108(1):109-20; Kagey, M. H., Melhuish, T. A., and Wotton, D. 2003. The polycomb protein Pc2 is a SUMO E3. Cell. 113(1):127-37). Once attached to cellular targets, SUMO modulates the function, subcellular localization, complex formation and/or stability of substrate proteins (Müller, S., Hoege, C., Pyrowolakis, G., and Jentsch, S. 2001. SUMO, ubiquitin's mysterious cousin. Nat Rev Mol Cell Biol. 2(3):202-10). SUMO-conjugation is reversible through the action of de-sumoylating enzymes called SENPs (Hay, R. T. 2007. SUMO-specific proteases: a twist in the tail. Trends Cell Biol. 17(8):370-6) and the SUMO proteins can then participate in additional conjugation cycles.
SAE-initiated SUMO-conjugation plays a major role in regulating diverse cellular processes, including cell cycle regulation, transcriptional regulation, cellular protein targeting, maintenance of genome integrity, chromosome segregation, and protein stability (Hay, R. T. 2005. SUMO: a history of modification. Mol Cell. 18(1):1-12; Gill, G. 2004. SUMO and ubiquitin in the nucleus: different functions, similar mechanisms? Genes Dev. 18(17):2046-59). For example, SUMO-conjugation causes changes in the subcellular localization of RanGAP1 by targeting it to the nuclear pore complex (Mahajan, R., Delphin, C., Guan, T., Gerace, L., and Melchior, F. 1997. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell. 88(1):97-1070). Sumoylation counteracts ubiquitination and subsequently blocks the degradation of IκB, thereby negatively regulating NF-κB activation (Desterro, J. M., Rodriguez, M. S., Hay, R. T. 1998. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell. 2(2):233-9). Sumoylation has been reported to play an important role in transcription exhibiting both repressive and stimulatory effects. Many of the transcriptional nodes that are modulated play important roles in cancer. For example, sumoylation stimulates the transcriptional activities of transcription factors such as p53 and HSF2 (Rodriguez, M. S., Desterro, J. M., Lain, S., Midgley, C. A., Lane, D. P., and Hay, R. T. 1999. SUMO-1 modification activates the transcriptional response of p53. EMBO J. 18(22):6455-61; Goodson, M. L., Hong, Y., Rogers, R., Matunis, M. J., Park-Sarge, O. K., Sarge, K. D. 2001. Sumo-1 modification regulates the DNA binding activity of heat shock transcription factor 2, a promyelocytic leukemia nuclear body associated transcription factor. J Biol Chem. 276(21):18513-8). In contrast, SUMO-conjugation represses the transcriptional activities of transcription factors such as LEF (Sachdev, S., Bruhn, L., Sieber, H., Pichler, A., Melchior, F., Grosschedl, R. 2001. PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev. 15(23):3088-103) and c-Myb (Bies, J., Markus, J., and Wolff, L. 2002. Covalent attachment of the SUMO-1 protein to the negative regulatory domain of the c-Myb transcription factor modifies its stability and transactivation capacity. J Biol Chem. 277(11):8999-9009). Thus, SUMO-conjugation controls gene expression and growth control pathways that are important for cancer cell survival.
Altered expression of SAE pathway components have been noted in a variety of cancer types: (Moschos, S. J., Jukic, D. M., Athanassiou, C., Bhargava, R., Dacic, S., Wang, X., Kuan, S. F., Fayewicz, S. L., Galambos, C., Acquafondata, M., Dhir, R., and Becker, D. 2010. Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues. Hum Pathol. 41(9):1286-980); including multiple myeloma (Driscoll, J. J., Pelluru, D., Lefkimmiatis, K., Fulciniti, M., Prabhala, R. H., Greipp, P. R., Barlogie, B., Tai, Y. T., Anderson, K. C., Shaughnessy, J. D. Jr., Annunziata, C. M., and Munshi, N. C. 2010. The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood. 115(14):2827-34); and breast cancer (Chen, S. F., Gong, C., Luo, M., Yao, H. R., Zeng, Y. J., and Su, F. X. 2011. Ubc9 expression predicts chemoresistance in breast cancer. Chin J Cancer. 30(9):638-44), In addition, preclinical studies indicate that Myc-driven cancers may be especially sensitive to SAE inhibition (Kessler, J. D., Kahle, K. T., Sun, T., Meerbrey, K. L., Schlabach, M. R., Schmitt, E. M., Skinner, S. O., Xu, Q., Li, M. Z., Hartman, Z. C., Rao, M., Yu, P., Dominguez-Vidana, R., Liang, A. C., Solimini, N. L., Bernardi, R. J., Yu, B., Hsu, T., Golding, I., Luo, J., Osborne, C. K., Creighton, C. J., Hilsenbeck, S. G., Schiff, R., Shaw, C. A., Elledge, S. J., and Westbrook, T. F. 2012. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 335(6066):348-53; Hoellein, A., Fallahi, M., Schoeffmann, S., Steidle, S., Schaub, F. X., Rudelius, M., Laitinen, I., Nilsson, L., Goga, A., Peschel, C., Nilsson, J. A., Cleveland, J. L., and Keller, U. 2014. Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. Blood. 124(13):2081-90). Since SUMO-conjugation regulates essential cellular functions that contribute to the growth and survival of tumor cells, targeting SAE could represent an approach to treat proliferative disorders such as cancer.
SAE inhibitors may also be applicable for the treatment of other diseases and conditions outside of oncology. For example, SUMO modifies proteins that play important roles in neurodegenerative diseases (Steffan, J. S., Agrawal, N., Pallos, J., Rockabrand, E., Trotman, L. C., Slepko, N., Illes, K., Lukacsovich, T., Zhu, Y. Z., Cattaneo, E., Pandolfi, P. P., Thompson, L. M., Marsh, J. L. 2004. SUMO modification of Huntington and Huntington's disease pathology. Science. 304(5667):100-4); Dorval, V., and Fraser, P. E. 2006. Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein. J Biol Chem. 281(15):9919-24; Ballatore, C., Lee, V. M., and Trojanowski, J. Q. 2007. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci. 8(9):663-72). Sumoylation also has been reported to play important role in pathogenic viral infection, inflammation and cardiac function (Lee, H. R., Kim, D. J., Lee, J. M., Choi, C. Y., Ahn, B. Y., Hayward, G. S., and Ahn, J. H. 2004. Ability of the human cytomegalovirus IE1 protein to modulate sumoylation of PML correlates with its functional activities in transcriptional regulation and infectivity in cultured fibroblast cells. J Virol. 78(12):6527-42; Liu, B., and Shuai, K. 2009. Summon SUMO to wrestle with inflammation. Mol Cell. 35(6):731-2; Wang, J., and Schwartz, R. J. 2010. Sumoylation and regulation of cardiac gene expression. Circ Res.107(1):19-29).
It would be beneficial therefore to provide new SAE inhibitors that possess good therapeutic properties, especially for the treatment of proliferative, inflammatory, cardiovascular and neurodegenerative disorders.
This application provides chemical entities which are inhibitors of SAE and accordingly are useful for the treatment of proliferative, inflammatory, cardiovascular and neurodegenerative disorders. The chemical entities of the present disclosure are chosen from:
and pharmaceutically acceptable salts thereof.
Also described herein, for reference purposes, are chemical entities represented by Formula ( I ):
or a pharmaceutically acceptable salt thereof;
wherein:
- stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry;
- Y is -O-, -CH2-, or -N(H)-;
- Ra is hydrogen, fluoro, -NH2, or hydroxyl;
- Ra' is hydrogen or fluoro, provided that when Ra is -NH2 or hydroxyl, Ra' is hydrogen;
- Rb is hydrogen or, together with the oxygen to which it is attached, forms a prodrug;
- Rc is hydrogen or C1-4 alkyl;
- Rd is hydrogen, halogen, -CF3, or C1-4 alkyl;
- X1 is C(H), C(F), or N;
- X2 is S or O;
- X3 is C(Rx3) or N;
- Rx3 is hydrogen, methyl, or halogen;
- Z1 is hydrogen, halogen, cyano, Rz3, -S-Rz3, -S(O)-Rz3, or -S(O)2-Rz3;
- Rz3 is an optionally substituted phenyl, an optionally substituted 5- to 7-membered cycloaliphatic, an optionally substituted 5- to 7-membered heterocyclyl, or an optionally substituted C1-4 aliphatic;
- wherein Z1 is not hydrogen, halogen, methyl, or cyano if Z2 is hydrogen or methyl; and (a) Z2 is a ring system having an optionally substituted 5- to 7-membered heterocyclyl with 1-2 heteroatoms or an optionally substituted 5- to 7-membered cycloaliphatic fused to (i) an optionally substituted 5-membered heteroaryl or an optionally substituted 6-membered aryl or heteroaryl to form a bicyclic group; or(ii) an optionally substituted 9-membered heteroaryl or an optionally substituted 10-membered aryl or heteroaryl to form a tricyclic group; OR(b) Z2 is L-Re wherein L is -L1-, -V1-L2-, or -L1-V1-L2-;
- L1 is a C1-3 alkylene chain wherein 1 or 2 saturated carbon atoms are optionally substituted by (Rf)(Rf') and in which there are optionally one or two degrees of unsaturation; each Rf is independently hydrogen; hydroxyl; -N(Rh)(Rh'); C1-4 aliphatic optionally substituted with hydroxyl, -OCH3, or cyclopropyl; -O-C1-4 aliphatic optionally substituted with hydroxyl, -OCH3, or cyclopropyl; or, together with Rf' and the carbon atom to which they are attached, form =CH2, or a 3- to 6-membered carbocycle or 4- to 6-membered heterocycle comprising a heteroatom chosen from N (which may be protonated or C1-4 alkylated), O, or S, the heteroatom optionally located immediately adjacent to the quaternary carbon of the heterocycle;each Rf' is independently hydrogen; C1-4 aliphatic optionally substituted with hydroxyl,-OCH3, or cyclopropyl; -O-C1-4 aliphatic optionally substituted with hydroxyl, -OCH3, or cyclopropyl; or, together with Rf and the carbon atom to which they are attached, form =CH2, or a 3- to 6-membered carbocycle or 4- to 6-membered heterocycle comprising a heteroatom chosen from N (which may be protonated or C1-4 alkylated), O, or S, the heteroatom optionally located immediately adjacent to the quaternary carbon of the heterocycle; wherein if Rf is hydroxyl, Rf' is not -O-C1-4 aliphatic optionally substituted with hydroxyl, -OCH3, or cyclopropyl;Rh and Rh' are each independently hydrogen or C1-4 alkyl;V1 is -S-, -O-, -S(O)-, -S(O)2-, -C(O)- or -N(Rg)-;L2 is a C0-2 alkylene chain wherein one saturated carbon atom is optionally substituted by (Rf)(Rf');Rg is hydrogen or C1-4 alkyl; andeither (i) Re is hydrogen, hydroxyl, halogen, -CF3, or an optionally substituted C1-4 aliphatic,with the proviso that Re is not hydrogen if Rf and Rf' are present and form a ring;OR (ii) Re is a ring chosen from optionally substituted 6-membered aryl, optionally substituted 5-to 6-membered heteroaryl, optionally substituted 3- to 7-membered cycloaliphatic, or optionally substituted 4- to 7-membered heterocyclyl, which is optionally fused to a second optionally substituted 6-membered aryl, optionally substituted 5-to 6-membered heteroaryl, optionally substituted 3- to 7-membered cycloaliphatic, or optionally substituted 4- to 7-membered heterocyclyl; OR
- Z2 is hydrogen.
- FIG. 1 is an XRPD pattern of compound I-257b Form 1.
- FIG. 2 is an XRPD pattern of compound I-263a Form 1.
- FIG. 3 is an XRPD pattern of compound I-256b Form 1.
- FIG. 4 shows a differential scanning calorimetry (DSC) thermogram for I-263a Form 1.
- FIG. 5 shows a thermogravimetric analysis (TGA) thermogram for I-263a Form 1.
- FIG. 6 shows a raman pattern for I-263a Form 1 including data in the region of 500 cm-1 to 3000 cm-1.
- FIG. 7 shows a raman pattern for I-263a Form 1 including data in the region of 200 cm-1 to 1600 cm-1.
- FIG. 8 shows a differential scanning calorimetry (DSC) thermogram for I-257b Form 1.
- FIG. 9 shows a thermogravimetric analysis (TGA) thermogram for I-257b Form 1.
- FIG. 10 shows a raman pattern for I-257b Form 1 including data in the region of 500 cm-1 to 3000 cm-1.
- FIG. 11 shows a raman pattern for I-257b Form 1 including data in the region of 200 cm-1 to 1600 cm-1.
- FIG. 12 shows a differential scanning calorimetry (DSC) thermogram for I-256b Form 1.
- FIG. 13 shows a thermogravimetric analysis (TGA) thermogram for I-256b Form 1.
- FIG. 14 is an XRPD pattern of compound I-263a Form 2.
- FIG. 15 is an XRPD pattern of compound I-263a Form 3.
- FIG. 16 shows a thermogravimetric analysis (TGA) thermogram for I-263a Form 3.
- FIG. 17 shows a differential scanning calorimetry (DSC) thermogram for I-263a Form 3.
As used herein, the following definitions shall apply unless otherwise indicated.
As described herein, chemical entities of the present disclosure may be optionally substituted with one or more substituents, such as are disclosed generally above, or as exemplified by particular classes, subclasses, and species disclosed herein. It will be appreciated that the phrase "optionally substituted" is used interchangeably with the phrase "substituted or unsubstituted." In general, the term "substituted," whether preceded by the term "optionally" or not, means that a hydrogen radical of the designated moiety is replaced with the radical of a specified substituent, provided that the substitution results in a stable or chemically feasible chemical entity. The term "substitutable," when used in reference to a designated atom, means that attached to the atom is a hydrogen radical, which hydrogen atom can be replaced with the radical of a suitable substituent. Unless otherwise indicated, an "optionally substituted" group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this disclosure are, for instance, those that result in the formation of stable or chemically feasible chemical entities.
A stable chemical entity or chemically feasible chemical entity is one in which the chemical structure is not substantially altered when kept at a temperature from about -80°C to about +40°C, in the absence of moisture or other chemically reactive conditions, for at least a week, or a chemical entity which maintains its integrity long enough to be useful for therapeutic or prophylactic administration to a patient.
The phrase "one or more substituents," as used herein, refers to a number of substituents that equals from one to the maximum number of substituents possible based on the number of available bonding sites, provided that the above conditions of stability and chemical feasibility are met.
As used herein, the term "independently selected" means that the same or different values may be selected for multiple instances of a given variable in a single chemical entity.
As used herein, "a 3-7-membered saturated, partially unsaturated, or aromatic monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10-membered partially unsaturated, or aromatic bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur" includes cycloaliphatic, heterocyclic, aryl and heteroaryl rings.
As used herein, the term "aromatic" includes aryl and heteroaryl groups as described generally below and herein.
The term "aliphatic" or "aliphatic group," as used herein, means an optionally substituted straight-chain or branched C1-12 hydrocarbon, or a cyclic C1-12 hydrocarbon which is completely saturated or which contains one or more units of unsaturation, but which is not aromatic (also referred to herein as "carbocycle," "cycloaliphatic," "cycloalkyl," or "cycloalkenyl"). For example, suitable aliphatic groups include optionally substituted linear, branched or cyclic alkyl, alkenyl, alkynyl groups and hybrids thereof, such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl, or (cycloalkyl)alkenyl. Unless otherwise specified, in various embodiments, aliphatic groups have 1-12, 1-10, 1-8, 1-6, 1-5, 1-4, 1-3, or 1-2 carbon atoms.
The term "alkyl," used alone or as part of a larger moiety, refers to an optionally substituted straight or branched chain saturated hydrocarbon group having 1-12, 1-10, 1-8, 1-6, 1-5, 1-4, 1-3, or 1-2 carbon atoms.
The term "alkenyl," used alone or as part of a larger moiety, refers to an optionally substituted straight or branched chain hydrocarbon group having at least one double bond and having 2-12, 2-10, 2-8, 2-6, 2-5, 2-4, or 2-3 carbon atoms.
The term "alkynyl," used alone or as part of a larger moiety, refers to an optionally substituted straight or branched chain hydrocarbon group having at least one triple bond and having 2-12, 2-10, 2-8, 2-6, 2-5, 2-4, or 2-3 carbon atoms.
The terms "cycloaliphatic," "carbocycle," "carbocyclyl," "carbocyclo," or "carbocyclic," used alone or as part of a larger moiety, refer to an optionally substituted saturated or partially unsaturated cyclic aliphatic ring system having from 3 to about 14 ring carbon atoms. In some embodiments, the cycloaliphatic group is an optionally substituted monocyclic hydrocarbon having 3-8 or 3-6 ring carbon atoms. Cycloaliphatic groups include, without limitation, optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl, or cyclooctadienyl. The terms "cycloaliphatic," "carbocycle," "carbocyclyl," "carbocyclo," or "carbocyclic" also include optionally substituted bridged or fused bicyclic rings having 6-12, 6-10, or 6-8 ring carbon atoms, wherein any individual ring in the bicyclic system has 3-8 ring carbon atoms.
The term "cycloalkyl" refers to an optionally substituted saturated ring system of about 3 to about 10 ring carbon atoms. Exemplary monocyclic cycloalkyl rings include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
The term "cycloalkenyl" refers to an optionally substituted non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and having about 3 to about 10 carbon atoms. Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl, and cycloheptenyl.
The terms "haloaliphatic," "haloalkyl," "haloalkenyl" and "haloalkoxy" refer to an aliphatic, alkyl, alkenyl or alkoxy group, as the case may be, which is substituted with one or more halogen atoms. As used herein, the term "halogen" or "halo" means F, Cl, Br, or I. The term "fluoroaliphatic" refers to a haloaliphatic wherein the halogen is fluoro, including perfluorinated aliphatic groups. Examples of fluoroaliphatic groups include, without limitation, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, 1,1,2-trifluoroethyl, 1,2,2-trifluoroethyl, and pentafluoroethyl.
The term "heteroatom" refers to one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR+ (as in N-substituted pyrrolidinyl)).
The terms "aryl" and "ar-," used alone or as part of a larger moiety, e.g., "aralkyl," "aralkoxy," or "aryloxyalkyl," refer to an optionally substituted C6-14 aromatic hydrocarbon moiety comprising one to three aromatic rings. In at least one embodiment, the aryl group is a C6-10 aryl group. Aryl groups include, without limitation, optionally substituted phenyl, naphthyl, or anthracenyl. The terms "aryl" and "ar-," as used herein, also include groups in which an aryl ring is fused to one or more cycloaliphatic rings to form an optionally substituted cyclic structure such as a tetrahydronaphthyl, indenyl, or indanyl ring. The term "aryl" may be used interchangeably with the terms "aryl group," "aryl ring," and "aromatic ring."
An "aralkyl" or "arylalkyl" group comprises an aryl group covalently attached to an alkyl group, either of which independently is optionally substituted. In at least one embodiment, the aralkyl group is C6-10 aryl C1-6 alkyl, including, without limitation, benzyl, phenethyl, and naphthylmethyl.
The terms "heteroaryl" and "heteroar-," used alone or as part of a larger moiety, e.g., "heteroaralkyl," or "heteroaralkoxy," refer to groups having 5 to 14 ring atoms, such as 5, 6, 9, or 10 ring atoms; having 6, 10, or 14 pi electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms. A heteroaryl group may be mono-, bi-, tri-, or polycyclic, for instance mono-, bi-, or tricyclic, such as mono- or bicyclic. In the context of "heteroar" entities, the term "heteroatom" refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. For example, a nitrogen atom of a heteroaryl may be a basic nitrogen atom and may also be optionally oxidized to the corresponding N-oxide. When a heteroaryl is substituted by a hydroxy group, it also includes its corresponding tautomer. The terms "heteroaryl" and "heteroar-," as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocycloaliphatic rings. Nonlimiting examples of heteroaryl groups include thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, pteridinyl, indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-1,4-oxazin-3(4H)-one. The term "heteroaryl" may be used interchangeably with the terms "heteroaryl ring," "heteroaryl group," or "heteroaromatic," any of which terms include rings that are optionally substituted. The term "heteroaralkyl" refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.
As used herein, the terms "heterocycle," "heterocyclyl," "heterocyclic radical," and "heterocyclic ring" are used interchangeably and refer to a stable 3- to 8-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, for instance one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR+ (as in N-substituted pyrrolidinyl).
A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and thiamorpholinyl. A heterocyclyl group may be mono-, bi-, tri-, or polycyclic, for instanct mono-, bi-, or tricyclic, and such as mono- or bicyclic. The term "heterocyclylalkyl" refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted. Additionally, a heterocyclic ring also includes groups in which the heterocyclic ring is fused to one or more aryl rings.
As used herein, the term "partially unsaturated" refers to a ring moiety that includes at least one double or triple bond between ring atoms. The term "partially unsaturated" is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aromatic (e.g., aryl or heteroaryl) moieties, as herein defined.
The term "alkylene" refers to a bivalent alkyl group. An "alkylene chain" is a polymethylene group, i.e., -(CH2)n-, wherein n is a positive integer, such as from 1 to 6, from 1 to 5, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3. An optionally substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms is optionally replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group and also include those described in the specification herein. It will be appreciated that two substituents of the alkylene group may be taken together to form a ring system. In certain embodiments, two substituents can be taken together to form a 3-7-membered ring. The substituents can be on the same or different atoms.
An alkylene chain also can be optionally interrupted by a functional group. An alkylene chain is "interrupted" by a functional group when an internal methylene unit is interrupted by the functional group. Examples of suitable "interrupting functional groups" are described in the specification and claims herein, and include double and/or triple bonds between carbons in the alkylene chain.
For purposes of clarity, all bivalent groups described herein, including, e.g., the alkylene chain linkers described above, are intended to be read from left to right, with a corresponding left-to-right reading of the formula or structure in which the variable appears.
An aryl (including aralkyl, aralkoxy, aryloxyalkyl and the like) or heteroaryl (including heteroaralkyl and heteroarylalkoxy and the like) group may contain one or more substituents and thus may be "optionally substituted." In addition to the substituents defined above and herein, suitable substituents on the unsaturated carbon atom of an aryl or heteroaryl group also include and are generally selected from -halo, -NO2, -CN, -R+, -C(R+)=C(R+)2, -C≡C-R+, -OR+, -SR°, -S(O)R°, -SO2R°, -SO3R+, -SO2N(R+)2, -N(R+)2, -NR+C(O)R+, -NR+C(S)R+, -NR+C(O)N(R+)2, -NR+C(S)N(R+) 2, -N(R+)C(=NR+)-N(R+)2, -N(R+)C(=NR+)-R°, -NR+CO2R+, -NR+SO2R°, -NR+SO2N(R+)2, -O-C(O)R+, -O-CO2R+, -OC(O)N(R+)2, -C(O)R+, -C(S)R°, -CO2R+, -C(O)-C(O)R+, -C(O)N(R+)2, -C(S)N(R+)2, -C(O)N(R+)-OR+, -C(O)N(R+)C(=NR+)-N(R)2, -N(R+)C(=NR+)-N(R+)-C(O)R+, -C(=NR+)-N(R+)2, -C(=NR+)-OR+, -N(R+)-N(R+)2, -C(=NR+)-N(R+)-OR+, -C(R°)=N-OR+, -P(O)(R+)2, -P(O)(OR+)2, -O-P(O)-OR+, and -P(O)(NR+)-N(R+)2, wherein R+, independently, is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, cycloaliphatic, or heterocyclyl group, or two independent occurrences of R+ are taken together with their intervening atom(s) to form an optionally substituted 5-7-membered aryl, heteroaryl, cycloaliphatic, or heterocyclyl. Each R° is, independently, an optionally substituted aliphatic, aryl, heteroaryl, cycloaliphatic, or heterocyclyl group.
An aliphatic or heteroaliphatic group, or a non-aromatic carbocyclic or heterocyclic ring may contain one or more substituents and thus may be "optionally substituted." Unless otherwise defined above and herein, suitable substituents on the saturated carbon of an aliphatic or heteroaliphatic group, or of a non-aromatic carbocyclic or heterocyclic ring are selected from those listed above for the unsaturated carbon of an aryl or heteroaryl group and additionally include the following: =O, =S, =C(R*)2, =N-N(R*)2, =N-OR*, =N-NHC(O)R*, =N-NHCO2R° =N-NHSO2R° or =N-R* where R° is defined above, and each R* is independently selected from hydrogen or an optionally substituted C1-6 aliphatic group.
In addition to the substituents defined above and herein, optional substituents on the nitrogen of a non-aromatic heterocyclic ring also include and are generally selected from -R+, -N(R+)2, -C(O)R+, -C(O)OR+, -C(O)C(O)R+, -C(O)CH2C(O)R+, -S(O)2R+, -S(O)2N(R+)2, -C(S)N(R+)2, -C(=NH)-N(R+)2, or -N(R+)S(O)2R+; wherein each R+ is defined above. A ring nitrogen atom of a heteroaryl or non-aromatic heterocyclic ring also may be oxidized to form the corresponding N-hydroxy or N-oxide chemical entity. A nonlimiting example of such a heteroaryl having an oxidized ring nitrogen atom is N-oxidopyridyl.
As detailed above, in some embodiments, two independent occurrences of R+ (or any other variable similarly defined in the specification and claims herein), are taken together with their intervening atom(s) to form a monocyclic or bicyclic ring selected from 3-13-membered cycloaliphatic,
3-12-membered heterocyclyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 6-10-membered aryl, or 5-10-membered heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
Exemplary rings that are formed when two independent occurrences of R+ (or any other variable similarly defined in the specification and claims herein), are taken together with their intervening atom(s) include, but are not limited to the following: a) two independent occurrences of R+ (or any other variable similarly defined in the specification or claims herein) that are bound to the same atom and are taken together with that atom to form a ring, for example, N(R+)2, where both occurrences of R+ are taken together with the nitrogen atom to form a piperidin-1-yl, piperazin-1-yl, or morpholin-4-yl group; and b) two independent occurrences of R+ (or any other variable similarly defined in the specification or claims herein) that are bound to different atoms and are taken together with both of those atoms to form a ring, for example where a phenyl group is substituted with two occurrences of OR+
these two occurrences of R+ are taken together with the oxygen atoms to which they are bound to form a fused 6-membered oxygen containing ring:
It will be appreciated that a variety of other rings (e.g., spiro and bridged rings) can be formed when two independent occurrences of R+ (or any other variable similarly defined in the specification and claims herein) are taken together with their intervening atom(s) and that the examples detailed above are not intended to be limiting.
Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present chemical entities are within the scope of the present disclosure. Unless otherwise stated, all tautomeric forms of the chemical entities disclosed herein are within the scope of the present disclosure. Additionally, unless otherwise stated, structures depicted herein are also meant to include chemical entities that differ only in the presence of one or more isotopically enriched atoms. For example, chemical entities having the present structures where there is a replacement of hydrogen by deuterium or tritium, or a replacement of a carbon by a 13C- or 14C-enriched carbon are within the scope of this disclosure. Such chemical entities are useful, as a nonlimiting example, as analytical tools or probes in biological assays.
It is to be understood that, when a disclosed chemical entity has at least one chiral center, the present disclosure encompasses one enantiomer of inhibitor free from the corresponding optical isomer, a racemic mixture of the inhibitor, and mixtures enriched in one enantiomer relative to its corresponding optical isomer. When a mixture is enriched in one enantiomer relative to its optical isomers, the mixture contains, for example, an enantiomeric excess of at least 50%, 75%, 90%, 95%, 99%, or 99.5%.
The enantiomers of the present disclosure may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts which may be separated, for example, by crystallization; formation of diastereoisomeric derivatives or complexes which may be separated, for example, by crystallization, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic esterification; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support for example silica with a bound chiral ligand or in the presence of a chiral solvent. Where the desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step is required to liberate the desired enantiomeric form. Alternatively, specific enantiomers may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer into the other by asymmetric transformation.
When a disclosed chemical entity has at least two chiral centers, the present disclosure encompasses a diastereomer free of other diastereomers, a pair of diastereomers free from other diasteromeric pairs, mixtures of diasteromers, mixtures of diasteromeric pairs, mixtures of diasteromers in which one diastereomer is enriched relative to the other diastereomer(s) and mixtures of diasteromeric pairs in which one diastereomeric pair is enriched relative to the other diastereomeric pair(s). When a mixture is enriched in one diastereomer or diastereomeric pair(s) relative to the other diastereomers or diastereomeric pair(s), the mixture is enriched with the depicted or referenced diastereomer or diastereomeric pair(s) relative to other diastereomers or diastereomeric pair(s) for the chemical entity, for example, by a molar excess of at least 50%, 75%, 90%, 95%, 99% or 99.5%.
The diastereoisomeric pairs may be separated by methods known to those skilled in the art, for example chromatography or crystallization and the individual enantiomers within each pair may be separated as described above. Specific procedures for chromatographically separating diastereomeric pairs of precursors used in the preparation of chemical entities disclosed herein are provided the examples herein.
For the avoidance of doubt, for chemical entities described herein, where the chemical entity is a single diastereomer and the absolute configuration of the chiral centers is known the name of the chemical entity reflects the assigned configuration at each stereochemical center; for example chemical entity I-43: {(1R,2S,4R)-4-[(5-{[4-(3-chlorobenzyl)-2-thienyl]carbonyl}pyrimidin-4-yl)amino]-2-hydroxycyclopentyl}methyl sulfamate. Where the chemical entity is a mixture of two or more diastereomers the name reflects the two or more possibilities by using "and" between the names of the individual diastereomers that make up the mixture; for example chemical entity I-1:
- [(1R,2R,3S,4R)-4-{[5-({4-[(1S)-1-(6-bromopyridin-2-yl)-1-hydroxyethyl]-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2,3-dihydroxycyclopentyl]methyl sulfamate and
- [(1R,2R,3S,4R)-4-{[5-({4-[(1R)-1-(6-bromopyridin-2-yl)-1-hydroxyethyl]-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2,3-dihydroxycyclopentyl]methyl sulfamate.
The chemical entity of the present disclosure is:
- [(1R,2S,4R)-4-{[5-({4-[7-chloro-1,2,3,4-tetrahydroisoquinoln-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate;
- [(1R,2S,4R)-4-{[5-({4-[7-chloro-3,4-dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate;
- [(1R,2S,4R)-4-{[5-({4-[3,4-dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate;
- or a pharmaceutically acceptable salt thereof.
In some embodiments, the chemical entity is:
- [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate;
- [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-3,4-dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate;
- [(1R,2S,4R)-4-{[5-({4-[(1R)-3,4-dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate;
- or a pharmaceutically acceptable salt thereof.
In some embodiments, a chemical entity is provided which is
or a pharmaceutically acceptable salt thereof.
| I-256b | [(1R,2S,4R)-4-{[5-({4-[(1R)-3,4-Dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate; |
| I-257b | [(1R,2S,4R)-4-{[5-({4-[(1R)-7-Chloro-3,4-dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate; |
| I-263a | [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate; |
Representative examples of the chemical entities of the disclosure are shown below in Table 1.
The chemical entities in Table 1 may also be identified by the following chemical names:
| I-256 | [(1R,2S,4R)-4-{[5-({4-[(1R)-3,4-dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate |
| and | |
| [(1R,2S,4R)-4-{[5-({4-[(1S)-3,4-dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate | |
| I-256a | [(1R,2S,4R)-4-{[5-({4-[(1S)-3,4-dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate |
| I-256b | [(1R,2S,4R)-4-{[5-( {4-[(1R)-3,4-dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate |
| I-257 | [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-3,4-dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate |
| and | |
| [(1R,2S,4R)-4-{[5-({4-[(1S)-7-chloro-3,4-dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate | |
| I-257a | [(1R,2S,4R)-4-{[5-({4-[(1S)-7-chloro-3,4-dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate |
| I-257b | [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-3,4-dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate |
| I-263a | [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate |
| I-263b | [(1R,2S,4R)-4-{[5-({4-[(1S)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate |
It will be appreciated that the chemical entities of this disclosure may be derivatized at functional groups to provide prodrug derivatives which are capable of conversion back to the parent chemical entities in vivo. Examples of such prodrugs include the physiologically acceptable and metabolically labile derivatives. More specifically, the prodrug of the chemical entity of this disclosure may be an ether or ester of the -OH group of the chemical entity. Prodrugs may be those in which Rb is -C(O)-Rbx, wherein Rbx has the values described herein, as discussed above. Furthermore, various approaches for providing prodrugs are known to those skilled in the art, as described in, e.g., Li et al., "Prodrugs of Nucleoside Analogues for Improved Oral Absorption and Tissue Targeting," J. Pharm. Sci. 97, 1109-34 (2008); Rautio et al., "Prodrugs: design and clinical applications," Nat. Rev. Drug Discovery 7, 255-270 (2008); and Rautio, Prodrugs and Targeted Delivery, Wiley-VCH (2011) (ISBN-10: 3527326030).
As used herein, "crystalline" refers to a solid in which the constituent atoms, molecules, or ions are packed in a regularly ordered, repeating three-dimensional pattern having a highly regular chemical structure. In particular, a crystalline compound or salt might be produced as one or more crystalline forms. For the purposes of this application, the terms "crystalline form" and "polymorph" are synonymous; the terms distinguish between crystals that have different properties (e.g., different XRPD patterns, different DSC scan results). Pseudopolymorphs are typically different solvates of a material, and thus the properties of pseudopolymorphs differ from one another. Thus, each distinct polymorph and pseudopolymorph is considered to be a distinct crystalline form herein.
"Substantially crystalline" refers to compounds or salts that are at least a particular weight percent crystalline. In some embodiments, the compound or salt is substantially crystalline. Examples of a crystalline form or substantially crystalline form include a single crystalline form or a mixture of different crystalline forms. Particular weight percentages include 50%, 60%, 70%, 75%, 80%, 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% and 99.9%. In some embodiments, substantially crystalline refers to compounds or salts that are at least 70% crystalline. In some embodiments, substantially crystalline refers to compounds or salts that are at least 80% crystalline. In some embodiments, substantially crystalline refers to compounds or salts that are at least 85% crystalline. In some embodiments, substantially crystalline refers to compounds or salts that are at least 90% crystalline. In some embodiments, substantially crystalline refers to compounds or salts that are at least 95% crystalline.
The term "hydrate" includes, for example, hemihydrates, monohydrates, sesquihydrates, dihydrates, and trihydrates. In some embodiments, a hydrate, such as a sesquihydrate, may be prepared by crystallization of a chemical entity disclosed herein from ethanol/distilled water. In some embodiments, a hydrate may be prepared by crystallization of a chemical entity disclosed herein from aqueous 50 mM citrate buffer at about pH 4.5.
The term "seeding" refers to the addition of crystalline material to a solution or mixture to initiate crystallization.
Some embodiments are directed to compounds or salts wherein at least a particular percentage by weight of the compound or salt is crystalline. Some embodiments are directed to a compound or salt wherein at least a particular percentage by weight of the compound or salt is crystalline. Particular weight percentages include 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% and 99.9%. When a particular percentage by weight of the compound or salt is crystalline, the remainder of the compound or salt is the amorphous form of the compound or salt. When a particular percentage by weight of the compound or salt is a designated crystalline form, the remainder of the compound or salt is some combination of the amorphous form of the compound or salt, and one or more crystalline forms of the compound or salt excluding the designated crystalline form.
When a crystalline form of a compound or salt is identified using one or more temperatures from a DSC profile (e.g., onset of endothermic transition, melt, etc.), each of the temperature values is understood to mean the given value ± 2 °C.
When a crystalline form of a compound or salt is identified using one or more peaks from a raman pattern expressed as cm-1, it is understood to mean the given value ± 0.2 cm-1, unless otherwise expressed.
Solid state forms of I-257b. Provided herein is an assortment of characterizing information, which is sufficient, but not all of which is necessary, to describe crystalline Form 1 anhydrous compound 1-257 ("I-257b Form 1").
| 7.0 | 2.7% |
| 9.4 | 5.6% |
| 10.2 | 7.5% |
| 13.0 | 13.4% |
| 14.5 | 62.5% |
| 17.5 | 10.5% |
| 18.2 | 15.4% |
| 18.6 | 96.8% |
| 19.1 | 29.0% |
| 20.7 | 41.5% |
| 21.4 | 23.8% |
| 21.7 | 74.8% |
| 22.6 | 53.9% |
| 24.0 | 30.0% |
| 24.8 | 19.1% |
| 25.2 | 100.0% |
| 25.8 | 27.2% |
| 26.7 | 12.6% |
| 27.0 | 5.9% |
| 27.9 | 38.0% |
| 29.1 | 2.7% |
In some embodiments, I-257b Form 1 is characterized by an XRPD pattern having a peak at 2θ angle 25.2°. In some embodiments, I-257b Form 1 is characterized by an XRPD pattern having peaks at 2θ angles of 25.2° and 18.6°. In some embodiments, I-257b Form 1 is characterized by an XRPD pattern having peaks at 2θ angles of 25.2°, 21.7°, 18.6°, and 14.5°. In some embodiments, I-257b Form 1 is characterized by an XRPD pattern having peaks at 2θ angles of 25.2°, 21.7°, 18.6°, 14.5°, 22.6°, 20.7° and 27.9°. In some embodiments, I-257b Form 1 is characterized by an XRPD pattern having peaks at 2θ angles of 25.2°, 21.7°, 18.6°, 14.5°, 22.6°, 20.7°, 27.9°, 24.0°, 19.1°, 25.8° and 21.4°. In some embodiments, the 2θ angles given above have an error tolerance of ±0.1°. In some embodiments, the 2θ angles given above have an error tolerance of ±0.2°. In some embodiments, the 2θ angles given above have an error tolerance of ±0.3°. In some embodiments, I-257b Form 1 is characterized by an XRPD pattern substantially as shown in Figure 1 .
In some embodiments, I-257b Form 1 is characterized by an XRPD pattern having a reference peak with a 2θ angle of 14.5 ± 0.3°, and having peaks at 2θ angles of 4.1°, 7.2°, and 10.7° relative to the reference peak. The term "reference peak" refers to a peak in the XRPD diffractogram that one skilled in the art considers as informing the polymorphic form of the material, i.e., differentiated from instrument noise. By "relative" it is meant that the observed 2θ angle of each peak will be the sum of the 2θ angle of the reference peak and the relative 2θ angle of that peak. For example, if the reference peak has a 2θ angle of 14.2°, the relative peaks will have 2θ angles of 18.3°, 21.4°, and 24.9°; if the reference peak has a 2θ angle of 14.3°, the relative peaks will have 2θ angles of 18.4°, 21.5°, and 25.0°; if the reference peak has a 2θ angle of 14.4°, the relative peaks will have 2θ angles of 18.5°, 21.6°, and 25.1°; etc. In some embodiments, I-257b Form 1 is characterized by an XRPD pattern having a reference peak with a 2θ angle of 14.5 ± 0.3°, and having peaks at 2θ angles of 4.1°, 6.2°, 7.2°, 8.1°, 10.7°, and 13.4° relative to the reference peak. In some embodiments, I-257b Form 1 is characterized by an XRPD pattern having a reference peak with a 2θ angle of 14.5 ± 0.3°, and having peaks at 2θ angles of 4.1°, 4.6°, 6.2°, 6.9°, 7.2°, 8.1°, 9.5°, 10.7°, 11.3°, and 13.4° relative to the reference peak. Any of the peaks that one skilled in the art considers as informing the polymorphic form of the material can serve as the reference peak and the relative peaks can then be calculated. For example, if the reference peak has a 2θ angle of 25.2°, then the relative peaks will have 2θ angles of -3.5°, -6.6°, and -10.7° relative to the reference peak.
In some embodiments, the chemical entity according to the disclosure is or comprises substantially crystalline I-257b Form 1. In some embodiments, the chemical entity according to the disclosure comprises at least 70% by weight crystalline I-257b Form 1. In some embodiments, the chemical entity according to the disclosure comprises at least 80% by weight crystalline I-257b Form 1. In some embodiments, the chemical entity according to the disclosure comprises at least 90% by weight crystalline I-257b Form 1. In some embodiments, the chemical entity according to the disclosure comprises at least 95% by weight crystalline I-257b Form 1.
In some embodiments, I-257b Form 1 is characterized by a raman pattern with a peak at 1450 cm-1. In some embodiments, I-257b Form 1 is characterized by a raman pattern with a peak at 1572 cm-1. In some embodiments, I-257b Form 1 is characterized by a raman pattern with a peak at 1422 cm-1. In some embodiments, I-257b Form 1 is characterized by a raman pattern with a peak at 754 cm-1. In some embodiments, I-257b Form 1 is characterized by a raman pattern with a peaks at 1450, 1572, 1422, and 754 cm-1. In some embodiments, I-257b Form 1 is characterized by a raman pattern with a peaks at 1450, 1572, and 1422 cm-1. In some embodiments, I-257b Form 1 is characterized by a raman pattern with a peaks at 1450 and 1572 cm-1.
In some embodiments, I-257b Form 1 is characterized by at least one of the following features (I-i)-(I-v):
- (I-i) an XRPD pattern having peaks at 2θ angles of 25.2°, 21.7°, 18.6°, and 14.5°;
- (I-ii) a DSC profile substantially as shown in FIG. 8;
- (I-iii) a TGA profile substantially as shown in FIG. 9;
- (I-iv) a raman pattern substantially as shown in FIG. 10;
- (I-v) a raman pattern substantially as shown in FIG. 11.
In some embodiments, I-257b Form 1 is characterized by at least two of the features (I-i)-(I-v). In some embodiments, I-257b Form 1 is characterized by at least three of the features (I-i)-(I-v). In some embodiments, I-257b Form 1 is characterized by at least four of the features (I-i)-(I-v). In some embodiments, I-257b Form 1 is characterized by all five of the features (I-i)-(I-v).
Solid state forms of I-263a. Provided herein is an assortment of characterizing information, which is sufficient, but not all of which is necessary, to describe crystalline Form 1 anhydrous compound I-263a ("I-263a Form 1").
| 4.7 | 8.1% |
| 7.1 | 11.7% |
| 9.5 | 10.8% |
| 9.7 | 13.1% |
| 13.3 | 5.5% |
| 14.1 | 9.0% |
| 15.1 | 18.5% |
| 16.3 | 13.7% |
| 17.0 | 13.6% |
| 17.7 | 6.6% |
| 17.9 | 12.6% |
| 18.2 | 12.0% |
| 18.9 | 29.4% |
| 19.5 | 37.2% |
| 20.1 | 10.1% |
| 20.5 | 9.2% |
| 21.6 | 100.0% |
| 22.6 | 7.2% |
| 23.5 | 14.6% |
| 24.6 | 6.1% |
| 26.3 | 19.6% |
| 27.2 | 21.2% |
| 28.8 | 13.6% |
In some embodiments, I-263a Form 1 is characterized by an XRPD pattern having a peak at 2θ angle 21.6°. In some embodiments, I-263a Form 1 is characterized by an XRPD pattern having peaks at 2θ angles of 21.6° and 19.5°. In some embodiments, I-263a Form 1 is characterized by an XRPD pattern having peaks at 2θ angles of 21.6°, 19.5°, 18.9°, and 27.2°. In some embodiments, I-263a Form 1 is characterized by an XRPD pattern having peaks at 2θ angles of 21.6°, 19.5°, 18.9°, 27.2°, 26.3°, 15.1°, and 23.5°. In some embodiments, I-263a Form 1 is characterized by an XRPD pattern having peaks at 2θ angles of 21.6°, 19.5°, 18.9°, 27.2°, 26.3°, 15.1°, 23.5°, 16.3°, 17.0°, 28.8°, and 9.7°. In some embodiments, the 2θ angles given above have an error tolerance of ±0.1°. In some embodiments, the 2θ angles given above have an error tolerance of ±0.2°. In some embodiments, the 2θ angles given above have an error tolerance of ±0.3°. In some embodiments, I-263a Form 1 is characterized by an XRPD pattern substantially as shown in Figure 2 .
In some embodiments, I-263a Form 1 is characterized by an XRPD pattern having a reference peak with a 2θ angle of 18.9 ± 0.3°, and having peaks at 2θ angles of 0.6°, 2.7°, and 8.3° relative to the reference peak. The term "reference peak" refers to a peak in the XRPD diffractogram that one skilled in the art considers as informing the polymorphic form of the material, i.e., differentiated from instrument noise. By "relative" it is meant that the observed 2θ angle of each peak will be the sum of the 2θ angle of the reference peak and the relative 2θ angle of that peak. For example, if the reference peak has a 2θ angle of 18.6°, the relative peaks will have 2θ angles of 19.2°, 21.3°, and 26.9°; if the reference peak has a 2θ angle of 18.7°, the relative peaks will have 2θ angles of 19.3°, 21.4°, and 27.0°; if the reference peak has a 2θ angle of 18.8°, the relative peaks will have 2θ angles of 19.4°, 21.5°, and 27.1°; etc. In some embodiments, I-263a Form 1 is characterized by an XRPD pattern having a reference peak with a 2θ angle of 18.9 ± 0.3°, and having peaks at 2θ angles of -3.8°, 0.6°, 2.7°, 4.6°, 7.4°, and 8.3° relative to the reference peak. In some embodiments, I-263a Form 1 is characterized by an XRPD pattern having a reference peak with a 2θ angle of 18.9 ± 0.3°, and having peaks at 2θ angles of -9.2°, -3.8°, -2.6°, -1.9°, 0.6°, 2.7°, 4.6°, 7.4°, and 8.3° and 9.9° relative to the reference peak. Any of the peaks that one skilled in the art considers as informing the polymorphic form of the material can serve as the reference peak and the relative peaks can then be calculated. For example, if the reference peak has a 2θ angle of 21.6°, then the relative peaks will have 2θ angles of -2.7°, -2.1°, and 5.6° relative to the reference peak.
In some embodiments, the chemical entity according to the disclosure is or comprises substantially crystalline I-263a Form 1. In some embodiments, the chemical entity according to the disclosure comprises at least 70% by weight crystalline I-263a Form 1. In some embodiments, the chemical entity according to the disclosure comprises at least 80% by weight crystalline I-263a Form 1. In some embodiments, the chemical entity according to the disclosure comprises at least 90% by weight crystalline I-263a Form 1. In some embodiments, the chemical entity according to the disclosure comprises at least 95% by weight crystalline I-263a Form 1.
In some embodiments, I-263a Form 1 is characterized by a raman pattern with a peak at 1441 cm-1. In some embodiments, I-263a Form 1 is characterized by a raman pattern with a peak at 1604 cm-1. In some embodiments, I-263a Form 1 is characterized by a raman pattern with a peak at 1583 cm-1. In some embodiments, I-263a Form 1 is characterized by a raman pattern with a peak at 1381 cm-1. In some embodiments, I-263a Form 1 is characterized by a raman pattern with a peaks at 1441, 1604, 1583, and 1381 cm-1. In some embodiments, I-263a Form 1 is characterized by a raman pattern with a peaks at 1441, 1604, and 1583 cm-1. In some embodiments, I-263a Form 1 is characterized by a raman pattern with a peaks at 1441 and 1604 cm-1.
In some embodiments, I-263a Form 1 is characterized by at least one of the following features (I-i)-(I-v):
- (I-i) an XRPD pattern having peaks at 2θ angles of 21.6°, 19.5°, 18.9°, and 27.2°;
- (I-ii) a DSC profile substantially as shown in FIG. 4;
- (I-iii) a TGA profile substantially as shown in FIG. 5;
- (I-iv) a raman pattern substantially as shown in FIG. 6;
- (I-v) a raman pattern substantially as shown in FIG. 7.
In some embodiments, I-263a Form 1 is characterized by at least two of the features (I-i)-(I-v). In some embodiments, I-263a Form 1 is characterized by at least three of the features (I-i)-(I-v). In some embodiments, I-263a Form 1 is characterized by at least four of the features (I-i)-(I-v). In some embodiments, I-263a Form 1 is characterized by all five of the features (I-i)-(I-v).
In some embodiments, the chemical entity I-263a is a hydrate. In some embodiments, the chemical entity I-263a is a sesquihydrate. In some embodiments, the chemical entity I-263a is a hydrate comprising between 2 and 3 equivalents of H2O.
I-263a Form 2. Provided herein is an assortment of characterizing information, which is sufficient, but not all of which is necessary, to describe crystalline Form 2 sesquihydrate compound I-263a ("I-263a Form 2"). I-263a Form 2 may be prepared by crystallization of I-263a from a solvent system containing water (e.g., distilled water) and an organic solvent such as methanol, ethanol, isopropyl alcohol, acetonitrile, formamide, or 1,4-dioxane.
| 3.1 | 21.4% |
| 9.4 | 6.2% |
| 10.1 | 4.4% |
| 10.9 | 12.7% |
| 11.9 | 11.2% |
| 13.0 | 32.8% |
| 14.2 | 4.0% |
| 15.5 | 5.9% |
| 16.8 | 6.0% |
| 17.9 | 7.3% |
| 19.0 | 100.0% |
| 19.5 | 4.4% |
| 20.4 | 4.2% |
| 21.1 | 10.2% |
| 22.0 | 28.3% |
| 22.4 | 12.2% |
| 22.9 | 6.0% |
| 24.0 | 9.4% |
| 25.1 | 10.2% |
| 26.2 | 11.6% |
| 27.1 | 14.0% |
| 31.4 | 6.3% |
In some embodiments, I-263a Form 2 is characterized by an XRPD pattern having a peak at 2θ angle 19.0°. In some embodiments, I-263a Form 2 is characterized by an XRPD pattern having peaks at 2θ angles of 19.0° and 13.0°. In some embodiments, I-263a Form 2 is characterized by an XRPD pattern having peaks at 2θ angles of 19.0°, 13.0°, 22.0° and 3.1°. In some embodiments, I-263a Form 2 is characterized by an XRPD pattern having peaks at 2θ angles of 19.0°, 13.0°, 22.0°, 3.1°, 27.1°, 10.9° and 22.4°. In some embodiments, I-263a Form 2 is characterized by an XRPD pattern having peaks at 2θ angles of 19.0°, 13.0°, 22.0°, 3.1°, 27.1°, 10.9°, 22.4°, 26.2°, 11.9°, 25.1° and 21.1°. In some embodiments, the 2θ angles given above have an error tolerance of ±0.1°. In some embodiments, the 2θ angles given above have an error tolerance of ±0.2°. In some embodiments, the 2θ angles given above have an error tolerance of ±0.3°. In some embodiments, I-263a Form 2 is characterized by an XRPD pattern substantially as shown in Figure 14 .
In some embodiments, I-263a Form 2 is characterized by an XRPD pattern having a reference peak with a 2θ angle of 3.1 ± 0.3°, and having peaks at 2θ angles of 9.9°, 15.9° and 18.9° relative to the reference peak. The term "reference peak" refers to a peak in the XRPD diffractogram that one skilled in the art considers as informing the polymorphic form of the material, i.e., differentiated from instrument noise. By "relative" it is meant that the observed 2θ angle of each peak will be the sum of the 2θ angle of the reference peak and the relative 2θ angle of that peak. For example, if the reference peak has a 2θ angle of 2.8°, the relative peaks will have 2θ angles of 12.7°, 18.7° and 21.7°; if the reference peak has a 2θ angle of 2.9°, the relative peaks will have 2θ angles of 12.8°, 18.8° and 21.8°; if the reference peak has a 2θ angle of 3.0°, the relative peaks will have 2θ angles of 12.9°, 18.9° and 21.9°; etc. In some embodiments, I-263a Form 2 is characterized by an XRPD pattern having a reference peak with a 2θ angle of 3.1 ± 0.3°, and having peaks at 2θ angles of 7.8°, 9.9°, 15.9°, 18.9°, 19.3° and 24.0° relative to the reference peak. In some embodiments, I-263a Form 2 is characterized by an XRPD pattern having a reference peak with a 2θ angle of 3.1 ± 0.3°, and having peaks at 2θ angles of 7.8°, 8.8°, 9.9°, 15.9°, 18.0°, 18.9°, 19.3°, 22.0°, 23.1° and 24.0° relative to the reference peak. Any of the peaks that one skilled in the art considers as informing the polymorphic form of the material can serve as the reference peak and the relative peaks can then be calculated. For example, if the reference peak has a 2θ angle of 19.0°, then the relative peaks will have 2θ angles of -15.9°, -6.0° and 3.0° relative to the reference peak.
Karl Fischer measurements of I-263a Form 2 show a water content of about 4.8%. A thermal gravimetric analysis (TGA) profile of I-263a Form 2 can show that the percent loss of weight of the sample as a function of temperature, the temperature rate change being about 10 °C/min, is approximately 5 % weight loss to 50.7°C. The TGA profile can also show that the percent loss of weight of the sample as a function of temperature, the temperature rate change being about 10 °C/min, is approximately 10.1 % weight loss to 252.8°C. A differential scanning calorimetry (DSC) profile of I-263a Form 2 can show the following regarding the heat flow as a function of temperature from a sample of I-263a Form 2, the temperature rate change being about 10 °C/min. In some embodiments, I-263a Form 2 is characterized by an endotherm event with a peak at about 47.7 °C. In some embodiments, I-263a Form 2 is characterized by an endotherm event with a peak at about 60.7 °C. In some embodiments, I-263a Form 2 is characterized by an endotherm event with a peak at about 73.8 °C. In some embodiments, I-263a Form 2 is characterized by an exotherm event with a peak at about 132.9 °C. In some embodiments, I-263a Form 2 is characterized by an exotherm event with a peak at about 149.3 °C.
In some embodiments, I-263a Form 2 is characterized by at least one of the following features (I-i)-(I-iv):
- (I-i) an XRPD pattern having peaks at 2θ angles of 3.1°, 13.0°, 19.0°, and 22.0° as shown in FIG. 14;
- (I-ii) a DSC profile characterized by at least two of an endotherm event with a peak at about 47.7 °C, an endotherm event with a peak at about 60.7 °C, an endotherm event with a peak at about 73.8 °C, an exotherm event with a peak at about 132.9 °C, and an exotherm event with a peak at about 149.3 °C;
- (I-iii) a TGA profile characterized by at least one of approximately 5 % weight loss to 50.7°C and approximately 10.1 % weight loss to 252.8°C
- (I-iv) a water content of about 4.8% according to Karl Fischer measurements.
In some embodiments, I-263a Form 2 is characterized by at least two of the features (I-i)-(I-iv). In some embodiments, I-263a Form 2 is characterized by at least three of the features (I-i)-(I-iv). In some embodiments, I-263a Form 2 is characterized by all four of the features (I-i)-(I-iv).
I-263a Form 3. Provided herein is an assortment of characterizing information, which is sufficient, but not all of which is necessary, to describe crystalline Form 3 hydrate compound I-263a ("I-263a Form 3"). I-263a Form 3 may be prepared by crystallization of I-263a from aqueous 50 mM citrate buffer at about pH 4.5.
| 9.0 | 14.0% |
| 9.9 | 19.8% |
| 12.4 | 23.2% |
| 14.6 | 14.9% |
| 15.6 | 100.0% |
| 16.2 | 55.0% |
| 17.1 | 18.8% |
| 17.8 | 24.1% |
| 18.0 | 44.1% |
| 18.3 | 21.9% |
| 19.2 | 35.0% |
| 19.4 | 27.0% |
| 20.0 | 39.3% |
| 20.3 | 26.7% |
| 20.7 | 26.3% |
| 21.3 | 18.4% |
| 21.8 | 25.6% |
| 22.3 | 29.2% |
| 23.1 | 31.4% |
| 23.9 | 15.4% |
| 24.9 | 17.9% |
| 25.4 | 25.6% |
| 27.2 | 13.2% |
In some embodiments, I-263a Form 3 is characterized by an XRPD pattern having a peak at 2θ angle 15.6°. In some embodiments, I-263a Form 3 is characterized by an XRPD pattern having peaks at 2θ angles of 15.6° and 16.2°. In some embodiments, I-263a Form 3 is characterized by an XRPD pattern having peaks at 2θ angles of 15.6°, 16.2°, 18.0° and 20.0°. In some embodiments, I-263a Form 3 is characterized by an XRPD pattern having peaks at 2θ angles of 15.6°, 16.2°, 18.0°, 19.2°, 20.0°, 22.3°, and 23.1°. In some embodiments, I-263a Form 3 is characterized by an XRPD pattern having peaks at 2θ angles of 15.6°, 16.2°, 18.0°, 19.2°, 20.0°, 22.3°, 23.1°, 20.3°, 20.7°, 21.8°, and 25.4°. In some embodiments, the 2θ angles given above have an error tolerance of ±0.1°. In some embodiments, the 2θ angles given above have an error tolerance of ±0.2°. In some embodiments, the 2θ angles given above have an error tolerance of ±0.3°. In some embodiments, I-263a Form 3 is characterized by an XRPD pattern substantially as shown in Figure 14 .
In some embodiments, I-263a Form 3 is characterized by an XRPD pattern having a reference peak with a 2θ angle of 15.6 ± 0.3°, and having peaks at 2θ angles of 0.6°, 2.4° and 4.4° relative to the reference peak. The term "reference peak" refers to a peak in the XRPD diffractogram that one skilled in the art considers as informing the polymorphic form of the material, i.e., differentiated from instrument noise. By "relative" it is meant that the observed 2θ angle of each peak will be the sum of the 2θ angle of the reference peak and the relative 2θ angle of that peak. For example, if the reference peak has a 2θ angle of 15.3°, the relative peaks will have 2θ angles of 15.9°, 17.7° and 19.7°; if the reference peak has a 2θ angle of 15.4°, the relative peaks will have 2θ angles of 16.0°, 17.8° and 19.8°; if the reference peak has a 2θ angle of 15.5°, the relative peaks will have 2θ angles of 16.1°, 17.9° and 19.9°; etc. In some embodiments, I-263a Form 3 is characterized by an XRPD pattern having a reference peak with a 2θ angle of 15.6 ± 0.3°, and having peaks at 2θ angles of 0.6°, 2.4°, 3.6°, 4.4°, 6.7°, and 7.5° relative to the reference peak. In some embodiments, I-263a Form 3 is characterized by an XRPD pattern having a reference peak with a 2θ angle of 15.6 ± 0.3°, and having peaks at 2θ angles of 0.6°, 2.4°, 3.6°, 4.4°, 4.7°, 5.1°, 6.2°, 6.7°, 7.5°, and 9.8° relative to the reference peak. Any of the peaks that one skilled in the art considers as informing the polymorphic form of the material can serve as the reference peak and the relative peaks can then be calculated. For example, if the reference peak has a 2θ angle of 18.0°, then the relative peaks will have 2θ angles of-2.4°, -1.8° and 2.0° relative to the reference peak.
In some embodiments, I-263a Form 3 of compound I-101 is characterized by at least one of the following features (I-i)-(I-iii):
- (I-i) an XRPD pattern having peaks at 2θ angles of 15.6°, 16.2°, 18.0°, and 20.0° as shown in FIGURE 15;
- (I-ii) a DSC profile substantially as shown in FIGURE 17;
- (I-iii) a TGA profile substantially as shown in FIGURE 16.
In some embodiments, I-263a Form 3 is characterized by at least two of the features (I-i)-(I-iii). In some embodiments, I-263a Form 3 is characterized by all three of the features (I-i)-(I-iii).
Solid state forms of I-256b. Provided herein is an assortment of characterizing information, which is sufficient, but not all of which is necessary, to describe crystalline Form 1 anhydrous compound I-256b ("I-256b Form 1").
| 11.9 | 10.1% |
| 14.8 | 9.9% |
| 15.5 | 15.4% |
| 16.3 | 37.4% |
| 17.5 | 28.3% |
| 18.7 | 34.8% |
| 18.9 | 44.0% |
| 19.7 | 20.2% |
| 20.1 | 45.9% |
| 20.6 | 30.0% |
| 21.1 | 100.0% |
| 21.8 | 15.1% |
| 22.8 | 55.5% |
| 23.3 | 32.1% |
| 24.1 | 23.8% |
| 25.8 | 10.2% |
| 26.2 | 10.3% |
| 27.0 | 38.3% |
| 27.5 | 23.6% |
| 27.8 | 19.6% |
| 28.8 | 5.4% |
In some embodiments, I-256b Form 1 is characterized by an XRPD pattern having a peak at 2θ angle 21.1°. In some embodiments, I-256b Form 1 is characterized by an XRPD pattern having peaks at 2θ angles of 21.1° and 22.8°. In some embodiments, I-256b Form 1 is characterized by an XRPD pattern having peaks at 2θ angles of 21.1°, 22.8°, 20.1°, and 18.9°. In some embodiments, I-256b Form 1 is characterized by an XRPD pattern having peaks at 2θ angles of 21.1°, 22.8°, 20.1°, 18.9°, 27.0°, 16.3°, and 18.7°. In some embodiments, I-256b Form 1 is characterized by an XRPD pattern having peaks at 2θ angles of 21.1°, 22.8°, 20.1°, 18.9°, 27.0°, 16.3°, 18.7°, 23.3°, 17.5°, 24.1°, and 27.5°. In some embodiments, the 2θ angles given above have an error tolerance of ±0.1°. In some embodiments, the 2θ angles given above have an error tolerance of ±0.2°. In some embodiments, the 2θ angles given above have an error tolerance of ±0.3°. In some embodiments, I-256b Form 1 is characterized by an XRPD pattern substantially as shown in Figure 3 .
In some embodiments, I-256b Form 1 is characterized by an XRPD pattern having a reference peak with a 2θ angle of 18.9 ± 0.3°, and having peaks at 2θ angles of 1.2°, 2.2°, and 3.9° relative to the reference peak. The term "reference peak" refers to a peak in the XRPD diffractogram that one skilled in the art considers as informing the polymorphic form of the material, i.e., differentiated from instrument noise. By "relative" it is meant that the observed 2θ angle of each peak will be the sum of the 2θ angle of the reference peak and the relative 2θ angle of that peak. For example, if the reference peak has a 2θ angle of 18.6°, the relative peaks will have 2θ angles of 19.8°, 20.8°, and 22.5°; if the reference peak has a 2θ angle of 18.7°, the relative peaks will have 2θ angles of 19.9°, 20.9°, and 22.6°; if the reference peak has a 2θ angle of 18.8°, the relative peaks will have 2θ angles of 20.0°, 21.0°, and 22.7°; etc. In some embodiments, I-256b Form 1 is characterized by an XRPD pattern having a reference peak with a 2θ angle of 18.9 ± 0.3°, and having peaks at 2θ angles of -2.6°, -0.2°, 1.2°, 2.2°, 3.9°, and 8.1° relative to the reference peak. In some embodiments, I-256b Form 1 is characterized by an XRPD pattern having a reference peak with a 2θ angle of ± 0.3°, and having peaks at 2θ angles of -2.6°, -1.4°, -0.2°, 1.2°, 2.2°, 3.9°, 4.4°, 5.2°, 8.1°, and 8.6° relative to the reference peak. Any of the peaks that one skilled in the art considers as informing the polymorphic form of the material can serve as the reference peak and the relative peaks can then be calculated. For example, if the reference peak has a 2θ angle of 21.1°, then the relative peaks will have 2θ angles of-2.2°, -1.0°, and 1.7° relative to the reference peak.
In some embodiments, the chemical entity according to the disclosure is or comprises substantially crystalline I-256b Form 1. In some embodiments, the chemical entity according to the disclosure comprises at least 70% by weight crystalline I-256b Form 1. In some embodiments, the chemical entity according to the disclosure comprises at least 80% by weight crystalline I-256b Form 1. In some embodiments, the chemical entity according to the disclosure comprises at least 90% by weight crystalline I-256b Form 1. In some embodiments, the chemical entity according to the disclosure comprises at least 95% by weight crystalline I-256b Form 1.
In some embodiments, I-256b Form 1 is characterized by at least one of the following features (I-i)-(I-iii):
- (I-i) an XRPD pattern having peaks at 2θ angles of 21.1°, 22.8°, 20.1°, and 18.9°;
- (I-ii) a DSC profile substantially as shown in FIG. 12;
- (I-iii) a TGA profile substantially as shown in FIG. 13.
In some embodiments, I-256b Form 1 is characterized by at least two of the features (I-i)-(I-iii). In some embodiments, I-256b Form 1 is characterized by at least three of the features (I-i)-(I-v). In some embodiments, I-256b Form 1 is characterized by at least four of the features (I-i)-(I-v). In some embodiments, I-256b Form 1 is characterized by all three of the features (I-i)-(I-iii).
As discussed above, the present disclosure provides chemical entities that are useful as inhibitors of SAE, and thus the present chemical entities can be useful for treating proliferative, inflammatory, cardiovascular and neurodegenerative disorders.
The chemical entities and pharmaceutical compositions of the present disclosure can be useful for the treatment of cancer. As used herein, the term "cancer" refers to a cellular disorder characterized by uncontrolled or disregulated cell proliferation, decreased cellular differentiation, inappropriate ability to invade surrounding tissue, and/or ability to establish new growth at ectopic sites. The term "cancer" includes, but is not limited to, solid tumors and bloodborne tumors (hematologic malignancies). The term "cancer" encompasses diseases of skin, tissues, organs, bone, cartilage, blood, and vessels. The term "cancer" further encompasses primary and metastatic cancers.
In some embodiments, therefore, the present disclosure provides the chemical entity disclosed herein for use in treating cancer. In some embodiments, the present disclosure provides a pharmaceutical composition (as described herein) for use in the treatment of cancer comprising the chemical entity disclosed herein.
Non-limiting examples of solid tumors that can be treated with the disclosed inhibitors include pancreatic cancer; bladder cancer including invasive bladder cancer; colorectal cancer; thyroid cancer, gastric cancer, breast cancer, including metastatic breast cancer; prostate cancer, including androgen-dependent and androgen-independent prostate cancer; renal cancer, including, e.g., metastatic renal cell carcinoma; liver cancer including e.g. hepatocellular cancer and intrahepatic bile duct; lung and bronchus cancer, including non-small cell lung cancer (NSCLC), squamous lung cancer, brochioloalveolar carcinoma (BAC), adenocarcinoma of the lung, and small cell lung cancer (SCLC); ovarian cancer, including, e.g., progressive epithelial or primary peritoneal cancer; cervical cancer; uterine cancer including e.g. uterine corpus and uterine cervix; endometrial cancer; gastric cancer; esophageal cancer; head and neck cancer, including, e.g., squamous cell carcinoma of the head and neck, nasopharyngeal caner, oral cavity and pharynx; melanoma; neuroendocrine cancer, including metastatic neuroendocrine tumors; brain cancer, including, e.g., glioma/glioblastoma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma; neuroendocrine, including metastatic neuroendocrine tumors; bone cancer; and soft tissue sarcoma.
Non-limiting examples of hematologic malignancies that can be treated with the disclosed inhibitors include acute myeloid leukemia (AML); chronic myelogenous leukemia (CML), including accelerated CML and CML blast phase (CML-BP); acute lymphoblastic leukemia (ALL); chronic lymphocytic leukemia (CLL); Hodgkin's disease (HD); non-Hodgkin's lymphoma (NHL), including follicular lymphoma and mantle cell lymphoma; B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL); T-cell lymphoma; multiple myeloma (MM); amyloidosis; Waldenstrom's macroglobulinemia; myelodysplastic syndromes (MDS), including refractory anemia (RA), refractory anemia with ringed siderblasts (RARS), (refractory anemia with excess blasts (RAEB), and RAEB in transformation (RAEB-T); small lymphocytic lymphoma (SLL); marginal zone lymphoma; smoldering multiple myeloma; and myeloproliferative syndromes.
In some embodiments, chemical entities of the present disclosure are suitable for the treatment of breast cancer, lung cancer, ovarian cancer, multiple myeloma, acute myeloid leukemia or acute lymphoblastic leukemia. In some embodiments, chemical entities of the present disclosure are suitable for the treatment of NHL. In some embodiments, chemical entities of the present disclosure are suitable for the treatment of indolent NHL. In some embodiments, chemical entities of the present disclosure are suitable for the treatment of follicular lymphoma, small lymphocytic lymphoma, mantle cell lymphoma or marginal zone lymphoma. In some embodiments, chemical entities of the present disclosure are suitable for the treatment of diffuse large B-cell lymphoma (DLBCL) or chronic lymphocytic lymphoma (CLL). In some embodiments, chemical entities of the present disclosure are suitable for the treatment of multiple myeloma. In some embodiments, chemical entities of the present disclosure are suitable for the treatment of ALL, AML, or MDS.
In other embodiments, chemical entities of the present disclosure are suitable for the treatment of inflammatory, cardiovascular and neurodegenerative disorders including, but not limited to, allergies/anaphylaxis, acute and/or chronic inflammation, rheumatoid arthritis, autoimmunity disorders, thrombosis, hypertension, cardiac hypertrophy, heart failure, Huntington's disease and Alzheimers.
Accordingly, in another aspect of the present disclosure, pharmaceutical compositions are provided, wherein these compositions comprise any of the chemical entities as described herein, and optionally comprise a pharmaceutically acceptable carrier, adjuvant or vehicle. In certain embodiments, these compositions optionally further comprise one or more additional therapeutic agents.
It will also be appreciated that certain of the chemical entities of present disclosure can exist in free form for treatment, or where appropriate, as a pharmaceutically acceptable derivative thereof. According to the present disclosure, a pharmaceutically acceptable derivative includes, but is not limited to, pharmaceutically acceptable prodrugs, salts, esters, salts of such esters, or any other adduct or derivative which upon administration to a patient in need is capable of providing, directly or indirectly, a chemical entity as otherwise described herein, or a metabolite or residue thereof.
As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and other mammals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. A "pharmaceutically acceptable salt" means any non-toxic salt or salt of an ester of a compound of this disclosure that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this disclosure or an inhibitorily active metabolite or residue thereof. As used herein, the term "inhibitorily active metabolite or residue thereof" means that a metabolite or residue thereof is also an inhibitor of SAE.
Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19. The chemical entities of this disclosure include pharmaceutically acceptable salts, such as those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(C1-4alkyl)4 salts. The present disclosure also envisions the quaternization of any basic nitrogen-containing groups of the chemical entities disclosed herein. Water or oil-soluble or dispersable products may be obtained by such quaternization. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
As described above, the pharmaceutically acceptable compositions of the present disclosure additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the chemical entities of the present disclosure, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of the present disclosure. Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers; alumina; aluminum stearate; lecithin; serum proteins, such as human serum albumin; buffer substances such as phosphates (including but not limited to phosphate buffer solutions), glycine, sorbic acid, or potassium sorbate; partial glyceride mixtures of saturated vegetable fatty acids; water; salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, and zinc salts; colloidal silica; magnesium trisilicate; polyvinyl pyrrolidone; polyacrylates; waxes; polyethylene-polyoxypropylene-block polymers; wool fat; sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; and non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate. Additionally, coloring agents; releasing agents; coating agents; sweetening, flavoring and perfuming agents; preservatives; and antioxidants can also be present in the composition, according to the judgment of the formulator. In some embodiments, pharmaceutically acceptable compositions of the disclosure comprise a compound disclosed herein (5 mg/mL); β-Cyclodextrin Sulfobutyl Ethers, Sodium Salts (Captisol®) (Ligand Pharmaceuticals Inc) (10% w/v); the composition being adjusted to a pH of 2 +/- 0.2 using 25 mM HCl and H3PO4; and Water for injection (q.s. to a fill volume, e.g., 5 mL or 10 mL). In some embodiments, pharmaceutically acceptable compositions of the disclosure comprise a compound disclosed herein (10 mg/mL); β-Cyclodextrin Sulfobutyl Ethers, Sodium Salts (Captisol®) (Ligand Pharmaceuticals Inc) (10% w/v); the composition being adjusted to a pH of 2 +/- 0.2 using 50mM H3PO4; and Water for injection (q.s. to a fill volume, e.g 10 mL).
Also described herein is a method for treating a proliferative, inflammatory, cardiovascular or neurodegenerative disorder comprising administering an effective amount of a chemical entity, or a pharmaceutical composition to a subject in need thereof. An "effective amount" of the chemical entity or pharmaceutical composition may be that amount effective for treating a proliferative, inflammatory, infectious, neurological or cardiovascular disorder, or is that amount effective for treating cancer. In other embodiments, an "effective amount" of a chemical entity may be an amount which inhibits binding of SAE.
The chemical entities and compositions, according to the present disclosure, may be administered using any amount and any route of administration effective for treating the disease. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like. The chemical entities of the present disclosure are frequently formulated in dosage unit form for ease of administration and uniformity of dosage. The expression "dosage unit form" as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the chemical entities and compositions of the present disclosure will be decided by the attending physician within the scope of sound medical judgment. The specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disease being treated and the severity of the disease; the activity of the specific chemical entity employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific chemical entity employed; the duration of the treatment; drugs used in combination or coincidental with the specific chemical entity employed, and like factors well known in the medical arts. The term "patient," as used herein, means an animal, for instance a mammal, such as a human.
The pharmaceutically acceptable compositions of the present disclosure can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, lotions, salves, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated. In certain embodiments, the chemical entities of the present disclosure may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg, for instance from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active chemical entities, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents, and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (for instance, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
In order to prolong the effect of a chemical entity of the present disclosure, it is often desirable to slow the absorption of the chemical entity from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the chemical entity then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered chemical entity form is accomplished by dissolving or suspending the chemical entity in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the chemical entity in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of chemical entity to polymer and the nature of the particular polymer employed, the rate of chemical entity release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the chemical entity in liposomes or microemulsions that are compatible with body tissues.
Compositions for rectal or vaginal administration are, for instance, suppositories which can be prepared by mixing the chemical entities of the present disclosure with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active chemical entity.
Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active chemical entity is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar--agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or for instance, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
The active chemical entities can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active chemical entity may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or for instance, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
Dosage forms for topical or transdermal administration of a chemical entity of the present disclosure include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of the present disclosure. Additionally, the present disclosure contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a chemical entity to the body. Such dosage forms can be made by dissolving or dispensing the chemical entity in the proper medium. Absorption enhancers can also be used to increase the flux of the chemical entity across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the chemical entity in a polymer matrix or gel.
In some embodiments, a chemical entity of the present disclosure or a pharmaceutical composition thereof is administered in conjunction with an anticancer agent. As used herein, the term "anticancer agent" refers to any agent that is administered to a subject with cancer for purposes of treating the cancer. Combination therapy includes administration of the therapeutic agents concurrently or sequentially. Alternatively, the therapeutic agents can be combined into one composition which is administered to the patient.
In one embodiment, the chemical entities of the present disclosure are used in combination with other therapeutic agents. In some embodiments, the additional therapeutic agent is selected from other inhibitors of SAE. In other embodiments, a chemical entity of the present disclosure is administered in conjunction with a therapeutic agent selected from the group consisting of cytotoxic agents, radiotherapy, and immunotherapy. In some embodiments, the chemical entities of the present disclosure can be used in combination with a chemotherapeutic regimen for the treatment of relapsed/refractory non-Hodgkin's lymphoma including DLBCL and CLL. Chemotherapeutic regimens include, but are not limited to R-ICE (rituximab, ifosfamide, carboplatin and etoposide), R-DHAP (rituximab, dexamethasone, high-dose cytarabine and cisplatin), and R-GDP (rituximab, gemcitabine, cisplatin and dexamethasone). It is understood that other combinations may be undertaken while remaining within the scope of the invention.
Those additional agents may be administered separately from a provided combination therapy, as part of a multiple dosage regimen. Alternatively, those agents may be part of a single dosage form, mixed together with a chemical entity of the present disclosure. If administered as part of a combination therapy, the two therapeutic agents may be submitted simultaneously, sequentially, or intermittently. Combination therapy can be used for any of the therapeutic indications described herein. In some embodiments, the combination therapy is for the treatment of a proliferative disorder (e.g., cancer) in a patient. In some embodiments, the proliferative disorder is breast cancer, lung cancer, ovarian cancer, multiple myeloma, acute myeloid leukemia or acute lymphoblastic leukemia.
Also described herein is a method for inhibiting SAE activity in a biological sample or a patient, which method comprises administering to the patient, or contacting said biological sample with a chemical entity disclosed herein, or a composition comprising said chemical entity. The term "biological sample," as used herein, generally includes in vivo, in vitro, and ex vivo materials, and also includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
Also described herein is a kit comprising separate containers in a single package, wherein a compound disclosed herein or a pharmaceutical composition and/or salt thereof is provided in combination with one or more pharmaceutically acceptable carriers for use in treating one or more disorders, symptoms and diseases where SAE plays a role.
The chemical entities of the present disclosure can be prepared by one of ordinary skill in the art in light of the present disclosure and knowledge in the art, and / or by reference to the schemes shown below and the synthetic examples. Exemplary synthetic routes are set forth in Schemes below and in the Examples.
Scheme 1 depicts the synthesis of aldehydes xxiii substituted with an isochroman ring. Lithiation of an appropriate bromide xx using alkyl lithium, such as n-BuLi or t-BuLi followed by addition of an aldehydes xxi gives the alcohols xxii (Method L). Under acidic conditions, such as aq. HCl/THF or TFA/water, cyclization and deprotection occur to form the aldehyde xxiii (Method M). Alternatively, deprotection of the primary silyl ethers, followed by activation of the primary alcohols, such as conversion to the iodide or mesylate, facilitates cyclization using Ag2O or base such as NaH in suitable solvent, such as Et2O or DMF. Deprotection of the acetals yields aldehydes xxiii (Method N).
Scheme 2 depicts an alternative synthesis of aldehydes xxviii substituted with an isochroman ring. Lithiation of an appropriate bromide using alkyl lithium, such as n-BuLi or t-BuLi, at cold temperature followed by addition of lactones xxv gives the ketones xxvi (Method O). Reduction of the ketone by reducing agent, such as NaBH4 in a suitable solvent, such as THF, provides alcoholsxxvii (Method P). Under acidic conditions, such as aq. HCl/THF or TFA/water cyclization and deprotection occur to form the aldehyde xxviii (Method Q). Alternatively, activation of the primary alcohols, such as conversion to the iodide or mesylate facilitates cyclization using Ag2O or base such as NaH in suitable solvent, such as Et2O or DMF. Deprotection of the acetals under acidic condition, such as aq. HCl/THF or TFA/water yields aldehydes xxviii (Method R).
Scheme 3 depicts the synthesis of aldehydes xxxii, substituted with a tetrahydroisoquinoline ring. Lithiation of an appropriate heteroaryl bromide using alkyl lithium, such as n-BuLi or t-BuLi at cold temperature and addition of dihydroisoquinolines (imine) xxix in the presence of Lewis acid, such as BF3 Et2O complex, gives the tetrahydroisoquinolines xxx (Method S). Protection of amines under general conditions, such as (Boc)2O/DMAP in acetonitrile, affords carbamates xxxi (Method T). Cleavage of the acetal group using acidic conditions, such as aq. HCl/THF or Dowex resin in suitable solvent, such as acetone, gives the aldehydes xxxii (Method J).
Scheme 4 depicts the synthesis of diaryl ketone intermediates lvii. Lithiation of bis-halogenated pyrimidines or pyridines lv can be followed by addition of the aldehydes liv to give diaryl alcohols lvi (Method AE). Oxidation for example with MnO2 or Dess-Martin periodinane provides diarylketones lvii (Method AF).
Scheme 5 depicts that the diarylketones lix can also be accessed by reaction of Weinreb amides lviii with bis-halogenated pyrimidines or pyridines lv (method AE).
Scheme 6 shows a synthetic route for the preparation of compounds of formula lxi and lxii. Diaryl ketones lvii can be treated with an appropriate amines, such as (1R,2S,3R,4R)-1-amino-2,3-(isopropylidenyl)dihydroxy-4-hydroxymethyl cyclopentane lix (prepared according to Claiborne, C.F. et al; PCT Application Publication WO 2008/019124 ) or lx in the presence of a suitable base, such as K2CO3, DIEA or TEA in a polar solvent, such as iPrOH, PrOH, nBuOH or DMF (Method AG).
Alternative amines can be used in this reaction (Method AG, scheme 6) such as those shown by the general formula lxiii and represented by lxiv through lxix in Diagram A below. Salts of the amine, such as the hydrochloride, can usually be used in this reaction with the appropriate equivalents of base. For amine lxiv see: Ober, M. et al. J. Am. Chem. Soc. 2005, 127, 18143-18149; for lxv see: Armitage, I. et al. US Patent Application Publication 2009/0036678 ; for lxvi, lxvii, lxix see: Biggadike, K. at al. J. Chem. Soc. Perkin Trans. 1988, 3, 549-554; Borthwick, A.D. et al. J. Med. Chem. 1990, 33, 179-186.
Scheme 7 depicts the synthesis of di-aryl ketone intermediates lxxiv. The alcohol intermediates lxx can be oxidized to the aldehydes lxxi (Method AF). The aldehydes lxxi can be reacted with appropriate Grignard reagents or organolithium reagents to give compounds of formula lxxii (Method AH). A suitable protection, such as TBS or TIPS group under general conditions (Method AI) and deprotection of the primary TBS ether under mild acidic conditions, such as 1% aq.HCl in ethanol, at cold temperature gives compounds of formula lxxiv (Method AJ).
Scheme 8 depicts the synthesis of keto aryl intermediates lxxviii. The alcohol intermediates lxxv are activated, for example by conversion to the bromide or chloride under standard conditions, such as PPh3 with CBr4 or CCl4 in suitable solvent, such as DCM, to give intermediate alkyl halides lxxvi (Method AK) and reacted with an appropriate amines in the presence of base, such as DIEA or Et3N to give amine derivatives lxxvii (Method AL). Additional nucleophiles may also be employed. For example, the bromide may be reacted with an alcohol or alkoxide to give ethers. The nitrogen nucleophile may be part of an aromatic ring, for example a pyrrole, imidazole, or indole. A suitable protection/deprotection strategy such as that shown at method AJ in scheme 8 gives the intermediates lxxviii.
Scheme 9 depicts the synthesis of keto aryl intermediates lxxxi where V1 is S or O. The alcohol is activated, for example by conversion to the bromide or chloride, and reacted with appropriate alcohol or thiol derivatives, such as optionally substituted phenols or benzenethiols, to give ether or thio ether intermediates lxxxi.
Scheme 10 illustrates the syntheses of compounds with general structure lxxxiv and lxxxv. A two-step sequence consisting of sulfamation and deprotection completes the synthesis of ketopyrimidines (ketopyridines) lxxxiv and lxxxv. The acetonide can be removed under acidic conditions, such as aq. HCl/THF or TFA/water, and the silyl group can be removed under acidic conditions, such as aq. HCl/THF H3PO4/acetonitrile or TFA/water, or by using an appropriate fluoride source, such as TBAF or TASF. If using a bis protected diol such as lxix the silyl group (TBS) can be selectively removed from the primary alcohol (e.g. mild acidic conditions at reduced temperature, such as 1% HCl in EtOH at 4 °C) prior to sulfamation. When using amines with unprotected alcohols, such as lxiv through lxviii, a suitable protecting group strategy can be employed to give the desired sulfamate. For example, protection of the free alcohols can be accomplished by prolonged treatment with TBSCl in DMF, which is then subjected to selective deprotection of the primary silyl group with mild acid at reduced temperature. Subsequent sulfamation and deprotection provides the desired sulfamate.
A selective sulfamation procedure can also be employed such as shown in scheme 11. The procedure employs a modified Burgess reagent (Armitage, I. et al. Org. Lett. 2012, 14, 2626-2629) followed by treatment with acid to deprotect the sulfamate (Method AO).
- AA
- LCMS method using ammonium acetate
- ACN
- acetonitrile
- aq
- aqueous
- Boc
- tert-butoxycarbonyl
- BPR
- back pressure regulator
- C
- Celsius
- CBS
- Corey-Bakshi-Shibata
- DCM
- methylene chloride
- DEA
- diethylamine
- DIAD
- diisopropyl azodicarboxylate
- DIBAl-H
- diisobutylaluminum hydride
- DIEA
- diisopropylethylamine
- DMA
- dimethylacetamide
- DMAP
- N,N-dimethyl-4-aminopyridine
- DME
- dimethyl ether
- DMF
- dimethylformamide
- DMSO
- dimethyl sulfoxide
- EtOAc
- ethyl acetate
- FA
- LCMS method using formic acid
- FR
- flow rate
- h
- hour(s)
- HPLC
- high performance liquid chromatography
- IC50
- inhibitory concentration 50%
- KHMDS
- potassium hexamethyldisilazide
- LAH
- lithium aluminium hydride
- LCMS
- liquid chromatography mass spectrometry
- LC
- liquid chromatography
- m/z
- mass to charge
- min
- minute(s)
- NBS
- N-bromosuccinimide
- NCS
- N-chlorosuccinimide
- NMM
- N-methylmorpholine
- NMP
- N-methylpyrrolidone
- NMR
- nuclear magnetic resonance
- PPh3
- Triphenylphosphine
- PPTS
- pyridinium p-toluenesulfonate
- psi
- pounds per square inch
- PTSA
- p-toluenesulfonic acid
- Rf
- retention factor
- rt
- room temperature
- SFC
- supercritical fluid chromatography
- STAB
- sodium triacetoxyborohydride
- TAS-F
- tris(dimethylamino)sulfonium difluorotrimethylsilicate
- TBAF
- tetra-n-butylammonium fluoride
- TBS
- tert-butyldimethylsilyl
- TEA
- triethylamine
- TEMPO
- 2,2,6,6-Tetramethylpiperidin-1-yl)oxyl
- TFA
- trifluoroacetic acid
- THF
- tetrahydrofuran
- TIPS
- triisopropylsilyl
- TLC
- thin layer chromatography
- TMS
- trimethylsilyl
NMR conditions: 1H NMR spectra are run on a 400 MHz Bruker unless otherwise stated.
LCMS spectra are recorded on a Hewlett-Packard HP1100 or Agilent 1100 Series LC system connected to a Micromass mass spectromteter using reverse phase C18 columns. Various gradients and run times are selected in order to best characterize the compounds. Mobile phases are based on ACN/water gradients and contain either 0.1% formic acid (methods indicated FA) or 10 mM ammonium acetate (methods indicated AA). One example of a solvent gradient that is used is 100% mobile phase A (mobile phase A = 99% water + 1% ACN + 0.1% formic acid) to 100% mobile phase B (mobile phase B = 95% ACN + 5% water + 0.1% formic acid) at a flow rate of 1 mL/min for a 16.5 min e.
One of ordinary skill in the art will recognize that modifications of the gradient, column length, and flow rate are possible and that some conditions may be more suitable for compound characterization than others, depending on the chemical species being analyzed.
A 1000mL round bottom flask was charged with 5-methyl-2-thiophenecarboxaldehyde (15 g, 120 mmol) and acetic acid (200 mL, 4000 mmol). Added pyridinium tribromide (48.5 g, 137 mmol). Heated in a 40 °C oil bath for 24 h. Reaction mixture was cooled to rt and poured into water (1L). Layers were separated, and the aqueous layer was extracted three times with EtOAc. Combined organics were washed with saturated NaHCO3 and then brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated. Subjected to ISCO chromatography eluting with a hexane / EtOAc gradient to afford the title compound as a white solid (yield = 11.44g). 1H NMR (400 MHz, Acetone-d6) δ 9.87 (s, 1H), 7.88 (s, 1H), 2.52 (s, 3H).
To a round bottom flask was added 4-bromo-5-methyl-2-thiophenecarbaldehyde (4.23 g, 20.6 mmol), 1,2-ethanediol (7.80 mL, 1.40E2 mmol), p-toluenesulfonic acid monohydrate (0.39 g, 2.1 mmol), and 100 ml toluene . The resulting reaction mixture was heated at reflux with a Dean-Stark trap overnight. The mixture was cooled to rt. EtOAc was added and the mixture was washed with saturated aqueous NaHCO3 and water. The organic layer was dried over Na2SO4, filtered, and concentrated. The residue was chromatographed (hexanes/EtOAc=9/1 as eluent) to give 4.2g of the title compound. 1H NMR (400 MHz, Chloroform-d) δ 6.99 (s, 1H), 6.02 (s, 1H), 4.15 - 4.09 (m, 2H), 4.06 - 3.99 (m, 2H), 2.40 (s, 3H).
To a solution of (2-bromo-4-chlorophenyl)acetic acid (25.0 g, 100 mmol in THF (400 mL, 5000 mmol) was added slowly 1.0 M of borane in THF (120.2 mL, 120.2 mmol) at rt. When bubbling ceased the resulting reaction mixture was heated at 60 °C overnight. Reaction was quenched via slow careful addition of 1.0 M of HCl in water (300 mL, 300 mmol). THF was removed in vacuo and the resulting residue was partitioned between Et2O and water. Layers were separated, and the aqueous layer was extracted 2 x Et2O. The combined organic solvents were dried, filtered and concentrated in vacuo. Crude yield: 23.1 g.
To a solution of the crude alcohol produced above (23.5 g, 99.8 mmol) in DCM (435.2 mL, 6789 mmol) was added 1H-imidazole (11.89 g, 174.6 mmol) followed by tert-butyldimethylsilyl chloride (22.56 g, 149.7 mmol) at rt, and the reaction was stirred for 24h. The reaction was quenched by addition of water (250 mL) and extracted with DCM (3x). The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by ISCO silica gel column chromatography (750g, Hexanes then 0-10% EtOAc/Hexanes over 50 min) to afford the title compound. Yield: 23.9 g (69% - 2 steps). 1H NMR (400 MHz, Chloroform-d) δ 7.57 (d, J = 1.3 Hz, 1H), 7.23 (d, J = 1.9 Hz, 2H), 3.83 (t, J = 6.7 Hz, 2H), 2.96 (t, J = 6.7 Hz, 2H), 0.89 (s, 9H), -0.00 (s, 6H).
A solution of [2-(2-bromo-4-chlorophenyl)ethoxy](tert-butyl)dimethylsilane (15.5 g, 44.3 mmol) in THF (197 mL, 2430 mmol) was cooled to -78 C, at which point was added 2.50 M of n-BuLi in hexane (24.8 mL, 62.0 mmol). After stirring for 5 min, DMF (5.15 mL, 66.5 mmol) was added, and the reaction mixture was stirred at -78 °C for 10 min. The reaction was quenched by adding saturated aq. NHaCl (150 mL) and then was warmed to rt. Reaction mixture was further diluted with water (60 mL, enough for complete dissolution of white solid). THF was removed in vacuo. Aqueous residue was diluted with Et2O (300 mL), the layers were separated, and the aqueous layer was extracted 2 x Et2O (70 mL each). Combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. Crude residue was loaded onto the column as a solution in hexane. Chromatography was performed (330 g column, 0-20% EtOAc:hexanes over 50 min) to afford the title compound. Yield = 12.7 g (96%). 1H NMR (400 MHz, Chloroform-d) δ 10.25 (s, 1H), 7.83 (d, J = 2.3 Hz, 1H), 7.50 - 7.45 (m, 1H), 3.83 (t, J = 6.2 Hz, 2H), 3.20 (t, J = 6.2 Hz, 2H), 0.81 (s, 9H), -0.09 (s, 6H).
To a 0°C cooled solution of N,N-dimethylaminoethanol (4.430 mL, 44.08 mmol) in hexane (25.0 mL, 191 mmol) was added a 2.5 M solution of n-BuLi in hexane(36.7 mL, 91.7 mmol), dropwise over 30 min via syringe. The reaction mixture was stirred at 0 °C then cooled to -78 °C. To the resulting mixture was added a solution of 5-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-2-chloropyridine (4.00 g, 14.7 mmol) in hexane (25.0 mL, 191 mmol), dropwise over 15 min, via syringe. The reaction mixture was stirred at -78 °C for 1 hour followed by addition of a solution of DMF (5.13 mL, 66.2 mmol) in THF (26 mL, 320 mmol), dropwise over 15 min, via syringe. The resulting solution was stirred at -78 °C for 1 hour then quenched with saturated aqueous NH4Cl and extracted with EtOAc. The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated to give 6.655 g of crude product as a brown oil. The crude material was purified by ISCO silica gel chromatography eluting with 0-5% EtOAc in hexanes to give 2.439 g of the title compound (55%). 1H NMR (400 MHz, Chloroform-d) δ 10.15 (s, 1H), 7.77 (d, J = 8.1 Hz, 1H), 7.50 (d, J = 8.1 Hz, 1H), 7.33 (s, 1H), 3.91 (t, J = 5.9 Hz, 2H), 3.32 (t, J = 5.9 Hz, 2H), 0.89 (s, 9H), -0.00 (s, 6H); LCMS (FA) M+1 300.1.
The compounds listed in the table below were prepared in an analogous fashion to that described above starting from the appropriate starting materials:
To a solution of 7-chloro-1,2,3,4-tetrahydro-isoquinoline (1.15 g, 6.86 mmol) in DCM (70.0 mL, 1090 mmol) was added MnO2 (5.96 g, 68.6 mmol) at rt, and the mixture was stirred for 16h. The reaction was filtered through a Celite pad and the residual solid was rinsed with DCM several times. The filtrate was concentrated in vacuo and the residue was purified by ISCO silica gel column chromatography (40g, eluting with 50% EtOAc in DCM, 50mL/min flow) to give 915 mg of the title compound as colorless solid. 1H NMR (400 MHz, DMSO-d6) δ 8.35 (t, J = 2.1 Hz, 1H), 7.52 (d, J = 2.2 Hz, 1H), 7.46 (dd, J = 8.0, 2.3 Hz, 1H), 7.28 (d, J = 8.0 Hz, 1H), 3.70 - 3.63 (m, 2H), 2.71 - 2.65 (m, 2H).
A solution of bromide Int-1 (1.70 g, 6.82 mmol) in THF (26.6 mL, 328 mmol) was cooled to -78 °C, and then 2.50 M of n-BuLi in hexane (2.940 mL, 7.349 mmol) was added and the mixture was stirred for 10 min at -78 °C. A solution of aldehyde Int-19 (1.39 g, 5.25 mmol) in THF (13.3 mL, 164 mmol) was then added, and the reaction was stirred for 10 min at -78 °C. The reaction was quenched by adding brine and then warmed to rt. The aqueous mixture was extracted 2 x EtOAc. The combined organic solvents were washed with brine, dried and concentrated in vacuo. The residue was purified by ISCO (80 g column, 0 to 20% EtOAc in hexanes as eluent) to afford the title compound as a pale yellow oil (yield = 1.96 g) that solidified upon standing in the refrigerator over the weekend. 1H NMR (400 MHz, Chloroform-d) δ 7.30 -7.26 (m, 2H), 7.26 - 7.21 (m, 2H), 7.07 (s, 1H), 6.09 (d, J = 2.7 Hz, 1H), 6.03 (s, 1H), 4.19 - 4.13 (m, 2H), 4.06 - 4.00 (m, 2H), 3.96 - 3.89 (m, 1H), 3.87 - 3.77 (m, 1H), 3.52 (d, J = 2.9 Hz, 1H), 3.06 (ddd, J = 14.3, 8.4, 6.2 Hz, 1H), 2.87 (dt, J = 13.9, 5.2 Hz, 1H), 2.37 (s, 3H), 0.86 (s, 9H), -0.00 (s, 3H), -0.01 (s, 3H).
A 100mL round bottom flask was charged with [2-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)phenyl][5-(1,3-dioxolan-2-yl)-2-methyl-3-thienyl]methanol (1.96 g, 4.51 mmol) and TFA (6.60 mL, 85.7 mmol) at rt. The resulting purple solution was stirred at rt overnight. The reaction mixture was carefully poured into saturated aqueous NaHCO3 (∼50 mL). The layers were separated, and the aqueous layer was extracted three times with EtOAc. The combined organic layers were washed with brine, then dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by ISCO (40 g column, 0 to 10% EtOAc in hexane as eluene) to afford the title compound as a pale brown oil (yield = 1.03 g). 1H NMR (400 MHz, Chloroform-d) δ 9.73 (s, 1H), 7.41 (s, 1H), 7.27 - 7.19 (m, 2H), 7.18 - 7.12 (m, 1H), 6.75 (d, J = 7.7 Hz, 1H), 5.86 (s, 1H), 4.21 (ddd, J = 11.3, 5.5, 3.7 Hz, 1H), 3.97 (ddd, J = 11.4, 9.7, 4.0 Hz, 1H), 3.16 (ddd, J = 15.9, 9.4, 5.4 Hz, 1H), 2.85 (dt, J = 16.6, 3.6 Hz, 1H), 2.59 (s, 3H).
An oven-dried 250mL 2-neck flask under nitrogen was charged with THF (100 mL) and cooled in an ice bath to -76 °C. To this was added 2.50 M n-BuLi in hexane (8.365 mL, 20.91 mmol) followed by a solution of 2-(4-bromothiophen-2-yl)-1,3-dioxolane (4.565 g, 19.42 mmol) in THF in small portions keeping the internal temperature less than -70 °C. Next, a solution of aldehyde Int-19 (3.95 g, 14.9 mmol) in THF (5 mL, 60 mmol) was added in a single portion quickly, during which the temperature increased to -45 °C. Reaction was immediately quenched by slowly adding saturated ammonium chloride solution, and then was warmed to rt. The layers were separated, and the aqueous layer was extracted three times with EtOAc. The combined organic portions were washed with brine; dried with anhydrous magnesium sulfate, filtered, and concentrated in vacuo. Crude residue was purified by column chromatography with a hexane / EtOAc gradient as eluent to provide the title compound as a yellow oil (yield = 4.20g). 1H NMR (400 MHz, Chloroform-d) δ 7.36 - 7.21 (m, 5H), 7.09 - 7.03 (m, 1H), 6.11 - 6.06 (m, 1H), 6.06 - 6.02 (m, 1H), 4.24 - 4.14 (m, 3H), 4.08 - 4.02 (m, 2H), 3.96 - 3.93 (m, 1H), 3.05 - 2.89 (m, 2H), 0.93 - 0.77 (m, 9H), 0.00 (s, 6H).
The compounds listed in the table below were prepared in an analogous fashion to that described in Example 96 starting from the appropriate starting materials:
| 7 |
A solution of 3,4-dihydroisoquinoline (500 mg, 3.81 mmol) in THF (15.4 mL) was cooled at - 30 °C. To this solution was added dropwise boron trifluoride etherate (0.53 mL, 4.19 mmol) at - 30 °C, and the mixture was stirred for 20 min. Into a separate 50 mL 2-neck flask 2.50 M of n-BuLi in hexane (1.83 mL, 4.57 mmol) was added at -78 °C followed by a solution of 2-(4-bromothiophen-2-yl)-1,3-dioxolane (1.08 g, 4.57 mmol) in THF (10.0 mL). After 5 min, lithiated thiophene suspension was added to the above solution of dihydroisoquinoline BF3-OEt2 complex at -78 °C. The reaction was stirred for 20 min at -78 °C and then quenched by addition of water. The layers were separated and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (0 to 5% MeOH in DCM). All fractions with Rf ranging from 0.1 to 0.25 in TLC (5% MeOH in DCM, ninhydrin stain) were combined to give 513 mg of a mixture of the title compound and some impurities as a red amorphous solid. This mixture was used for the next step without further purification.
The crude mixture from step 1was dissolved in MeCN (6.97 mL), to which was added (Boc)2O (1.25 g, 5.72 mmol) and N,N-dimethylaminopyridine (2.33 mg, 19.1 µmol) at rt. After stirring for 2 h, the reaction was quenched by adding water. The layers were separated and the aqueous layer was extracted with EtOAc 2x. The combined organics were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (0 to 20% EtOAc in hexane) to give 393 mg (27% for 2 steps) of the title compound.1H NMR (400 MHz, Chloroform-d) δ 7.26 - 7.03 (m, 6H), 6.82 (s, 1H), 6.01 (s, 1H), 4.17 - 3.93 (m, 5H), 3.20 - 3.04 (m, 1H), 3.04 - 2.86 (m, 1H), 2.79 - 2.68 (m, 1H), 1.57 - 1.46 (m, 9H); LCMS (FA): m/z = 388.3 (M+H).
To a solution of tert-butyl 1-[5-(1,3-dioxolan-2-yl)-3-thienyl]-3,4-dihydroisoquinoline-2(1H)-carboxylate (393 mg, 1.01 mmol) in acetone (7.72 mL) was added 500 mg of Dowex 50WX-2-200 (H)(acid resin), and the mixture was shaken for 18 h at rt. The reaction was filtered through a glass frit funnel and the residual resin was rinsed with acetone several times. To the filtrate was added saturated aqueous NaHCO3 (25.0 mL) and the mixture was concentrated to half volume in vacuo. The residue was diluted with EtOAc, the layers were separated, and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (0 to 15% EtOAc in hexane) to give 319 mg (91%) of the title compound as a colorless amorphous solid. 1H NMR (400 MHz, Chloroform-d) δ 9.84 (s, 1H), 7.64 (s, 1H), 7.30 - 7.07 (m, 5H), 6.48 - 6.23 (br s, 1H), 4.09 - 3.88 (m, 1H), 3.22 - 3.06 (m, 1H), 3.05 - 2.89 (m, 1H), 2.81 - 2.69 (m, 1H), 1.52 (s, 9H).
To a solution of tert-butyl 7-chloro-1-[5-(1,3-dioxolan-2-yl)-2-methyl-3-thienyl]-3,4-dihydroisoquinoline-2(1H)-carboxylate (7.30 g, 16.7 mmol) in methanol (200 mL) and water (20 mL) was added a solution of HCl (4.00 mL, 130 mmol) in methanol (200 mL) and the reaction as stirred at rt for 1 hour. Reaction was quenched via addition of 50 mL of saturated NaHCO3 with stirring for 5 min. MeOH was removed in vacuo, and the resulting aqueous mixture was diluted with EtOAc, the layers were separated, and the aqueous layer was extracted three times with EtOAc. The combined organic portions were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified via silica gel chromatography eluting with a hexane / EtOAc gradient to afford the title compound (4.55g, 70%). 1H NMR (400 MHz, Chloroform-d) δ 9.67 (s, 1H), 7.27 - 7.15 (m, 2H), 7.12 (s, 1H), 6.98 - 6.94 (m, 1H), 6.34 (m, 1H), 4.15 (s, 1H), 3.18 - 3.06 (m, 1H), 3.05 - 2.93 (m, 1H), 2.82 - 2.73 (m, 1H), 2.69 (s, 3H), 1.50 (s, 9H). LCMS: (AA) M+Na 414.2
The compounds listed in the table below were prepared in an analogous fashion to that described in Reference Example 100 starting from the appropriate starting materials:
A solution of tert-butyl [(1R,3S,4R)-3-hydroxy-4-(hydroxymethyl)cyclopentyl]carbamate (4.0 g, 17 mmol) (for synthesis of starting material see: Ober, M. et. al. J. Am. Chem. Soc. 2005, 127, 18143-18149.) and imidazole (1.4 g, 21 mmol) in DMF (40 mL) was diluted with DCM (200 mL) and cooled in an ice/water bath. tert-Butyldimethylsilylchloride (2.9 g, 19 mmol) was added as a solution in DCM (40 mL). The reaction was allowed to warm to rt and stirred for 16 h. The reaction was quenched by addition of water (150 mL) and the mixture was transferred to separatory funnel. The organic layer was collected and the residual water layer was extracted with DCM (150 mL x2). The combined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was purified on silica gel to provide the title compound (5.21 g, 87%). 1H NMR (CDCl3) δ 4.73 (s, 1H), 4.20 - 4.05 (m, 2H), 3.81 (dd, J = 9.8, 4.2 Hz, 1H), 3.54 (dd, J = 9.7, 7.1 Hz, 1H), 2.33 - 2.10 (m, 2H), 2.05 - 1.79 (m, 3H), 1.43 (s, 9H), 1.20 - 1.08 (m, 1H), 0.90 (s, 9H), 0.08 (s, 6H).
To a solution of tert-butyl [(1R,3R,4S)-3-({[tert-butyl(dimethyl)silyl]oxy}methyl)-4-hydroxycyclopentyl]carbamate (3.8 g, 11 mmol) in DMF (57 mL) under an atmosphere of argon was added imidazole (2.25 g, 33 mmol) followed by triisopropylchlorosilane (4.7 mL, 22 mmol) at RT, and the mixture was stirred for 61 h. The reaction was quenched by addition of saturated NH4Cl (150 mL) and extracted with EtOAc (200 mLx5). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified on silica gel to afford the title compound (5.13 g, 93%) as a colorless oil. 1H NMR (CDCl3) δ 4.90 (s, 1H), 4.35 - 4.20 (m, 1H), 4.19 - 3.99 (m, 1H), 3.75 - 3.44 (m, 2H), 2.37 - 2.17 (m, 1H), 2.03 (s, 1H), 1.96 - 1.69 (m, 2H), 1.43 (s, 9H), 1.31 - 1.13 (m, 1H), 1.04 (s, 2H), 0.90 (s, 9H), 0.06 (s, 6H).
To solution of tert-butyl {(1R,3R,4S)-3-({[tert-butyl(dimethyl)silyl]oxy}methyl)-4-[(triisopropylsilyl)oxy]cyclopentyl}carbamate (1.5 g, 3.0 mmol) in DCM (100 mL) was added EtOH (0.38 mL, 6.6 mmol) followed by zinc bromide (5.4 g, 24 mmol) at RT, and the mixture was stirred for 37 h. The reaction was quenched by addition of IN NaOH (100 mL) and extracted with DCM (100 mL x5). The combined organic layers were washed with brine and then dried over Na2SO4. After filtration, the filtrate was concentrated in vacuo. The residue was purified on silica gel to give the title compound (1.09 g, 91%) as a colorless oil. LCMS (FA): m/z = 402.6 (M+H).
A 1-neck 3L round bottom flask was charged with (1R,3R,4S)-3-({[tert-butyl(dimethyl)silyl]oxy}methyl)-4-[(triisopropylsilyl)oxy]cyclopentanamine (45.0 g, 112 mmol) and a solution of 12 M of HCl in water (20.0 mL, 240 mmol) in ethanol (2000 mL) was added. The reaction was stirred at RT for 3 h. The reaction was quenched by addition of a solution of sodium carbonate (26.7 g, 252 mmol) in water (130 mL), stirred 5 min, then concentrated. The residue was azeotroped from ethanol several times to give a brown solid. DCM (1000 mL) was added and the mixture was stirred at RT overnight, filtered to remove inorganic solids and evaporated filtrate to dryness. The residue was subjected to flash column chromatography (eluting with DCM then 95 DCM / 5 MeOH / 0.5 NH4OH) to give 26.6 g (83%) of the title compound. 1H NMR (400 MHz, DMSO-d 6) δ 4.22 - 4.15 (m, 1H), 3.42 - 3.25 (m, 4H), 2.07 - 1.96 (m, 1H), 1.96 - 1.84 (m, 1H), 1.74 - 1.64 (m, 1H), 1.56 - 1.45 (m, 1H), 1.02 (s, 21H).
A solution of bromide Int-1 (1.70 g, 6.82 mmol) in THF (26.6 mL) was cooled to -78 °C, and then 2.50 M of n-BuLi in hexane (2.94 mL, 7.34 mmol) was added and the mixture was stirred for 10 min at -78 °C. A solution of aldehyde Int-19 (1.39 g, 5.25 mmol) in THF (13.3 mL, 164 mmol) was then added, and the reaction was stirred for 10 min at -78 °C. The reaction was quenched by adding brine and then warmed to rt. The aqueous mixture was extracted 2 × EtOAc. The combined organic solvents were washed with brine, dried and concentrated in vacuo. The residue was purified by flash column chromatography (0 to 20% EtOAc in hexanes as eluent) to afford the title compound as a pale yellow oil (yield = 1.96 g) that solidified upon standing in the refrigerator over the weekend. 1H NMR (400 MHz, Chloroform-d) δ 7.30 - 7.26 (m, 2H), 7.26 - 7.21 (m, 2H), 7.07 (s, 1H), 6.09 (d, J = 2.7 Hz, 1H), 6.03 (s, 1H), 4.19 - 4.13 (m, 2H), 4.06 - 4.00 (m, 2H), 3.96 - 3.89 (m, 1H), 3.87 - 3.77 (m, 1H), 3.52 (d, J = 2.9 Hz, 1H), 3.06 (ddd, J = 14.3, 8.4, 6.2 Hz, 1H), 2.87 (dt, J = 13.9, 5.2 Hz, 1H), 2.37 (s, 3H), 0.86 (s, 9H), -0.00 (s, 3H), -0.01 (s, 3H).
To a solution of [2-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)phenyl][5-(1,3-dioxolan-2-yl)-2-methyl-3-thienyl]methanol (11.4 g, 26.2 mmol) in DCM (77.9 mL) was added MnO2 (22.8 g, 262 mmol) at rt and the reaction was stirred for 24 h. The reaction was filtered through a Celite pad and the residual solid was rinsed with DCM several times. The filtrate was concentrated in vacuo and the residue was purified by silica gel column chromatography (5% EtOAc in hexane) to give 9.58 g (84%) of the title compound as a colorless solid. 1H NMR (400 MHz, Chloroform-d) δ 7.41 - 7.31 (m, 2H), 7.32 - 7.21 (m, 2H), 7.03 (s, 1H), 5.91 (s, 1H), 4.15 - 4.04 (m, 2H), 4.03 - 3.93 (m, 2H), 3.78 (t, J = 7.0 Hz, 2H), 2.89 (t, J = 7.0 Hz, 2H), 2.65 (s, 3H), 0.83 (s, 9H), -0.06 (s, 6H); LCMS (FA): m/z = 433.2 (M+H).
To a solution of [2-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)phenyl][5-(1,3-dioxolan-2-yl)-2-methyl-3-thienyl]methanone (13.8 g, 32.0 mmol) in THF (448 mL) was added 0.5 M of (S)-(-)-o-tolyl-CBS-oxazaborolidine in toluene (32.0 mL, 16.0 mmol), followed by 1.00 M of BH3-THF complex in THF (35.2 mL, 35.2 mmol) at rt. After stirring for 1 h at rt, the reaction was quenched by addition of MeOH. The mixture was stirred for 25 min, and then the volatiles were removed in vacuo. The residue was dissolved in EtOAc and water and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (10 to 30% EtOAc in hexane) to provide 14.6 g of the alcohol intermediate. The obtained alcohol was dissolved in THF (290 mL) and TBAF hydrate (10.7 g, 38.4 mmol) was added to the solution. After stirring for 10 min at 40 °C, the reaction was concentrated in vacuo. To the residue was added water and the mixture was extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (30 to 80% EtOAc in hexane) to give 9.86 g (94% over two steps) of the title compound as a colorless oil. The enantiomeric purity was determined to be 87% ee by HPLC (80/20/0.1 hexane/EtOH/DEA; 1.0 mL/min for 20 min; using a CHIRALPAK ID column (4.6 × 250 mm)): 8.65 min (minor) and 12.8 min (major). 1H NMR (400 MHz, DMSO-d 6) δ 7.50 (d, J = 7.4 Hz, 1H), 7.25 - 7.11 (m, 3H), 6.73 (s, 1H), 5.89 (d, J = 4.5 Hz, 1H), 5.84 (s, 1H), 5.59 (d, J = 4.5 Hz, 1H), 4.68 (t, J = 5.1 Hz, 1H), 4.00 - 3.92 (m, 2H), 3.90 - 3.81 (m, 2H), 3.54 - 3.36 (m, 2H), 2.74 - 2.58 (m, 2H), 2.39 (s, 3H); LCMS (FA) m/z = 304.1 (M+H-18).
To a solution of 2-{2-[(R)-[5-(1,3-dioxolan-2-yl)-2-methyl-3-thienyl](hydroxy)methyl]phenyl}ethanol (10.4 g, 32.4 mmol) in benzene (380 mL) were added pyridine (7.93 mL, 98.0 mmol) and PPh3 (12.8 g, 49.0 mmol), followed by I2 (8.63 g, 34.0 mmol). After stirring overnight at rt, the reaction mixture was filtered and the filter cake was rinsed with Et2O. To the filtrate was added water and hexane, the layers were separated, and the aqueous layer was extracted with hexane. The combined organic layers were washed with brine, then dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (10 to 20% EtOAc in hexane) to afford 10 g (73%) of the title compound as a pale yellow solid. 1H NMR (400 MHz, Chloroform-d) δ 7.62 (d, J = 7.5 Hz, 1H), 7.29 (d, J = 25.4 Hz, 2H), 7.15 (d, J = 7.3 Hz, 1H), 6.78 (s, 1H), 6.02 (s, 1H), 5.91 (s, 1H), 4.16 - 4.02 (m, 2H), 4.02 - 3.90 (m, 2H), 3.23 - 3.03 (m, 3H), 3.01 - 2.92 (m, 1H), 2.51 (s, 3H), 1.99 (d, J = 3.0 Hz, 1H).
To a solution of (R)-[5-(1,3-dioxolan-2-yl)-2-methyl-3-thienyl][2-(2-iodoethyl)phenyl]methanol (10.2 g, 23.7 mmol) in Et2O (366 mL) was added silver(I) oxide (27.4 g, 118 mmol) and the reaction was stirred for two days at rt. The reaction was filtered through a Celite pad and the residual solid was rinsed with Et2O several times. The filtrate was concentrated in vacuo and the residue was purified by silica gel column chromatography (30% EtOAc in hexane) to give 7.01g (98%) of the title compound as a colorless oil. 1H NMR (400 MHz, Chloroform-d) δ 7.22 - 7.05 (m, 3H), 6.78 - 6.72 (m, 2H), 5.92 (s, 1H), 5.77 (s, 1H), 4.19 (ddd, J = 11.3, 5.5, 3.6 Hz, 1H), 4.12 - 4.03 (m, 2H), 4.01 - 3.86 (m, 3H), 3.11 (ddd, J = 15.9, 9.4, 5.7 Hz, 1H), 2.78 (dt, J = 16.5, 3.6 Hz, 1H), 2.46 (s, 3H).
To a solution of (1R)-1-[5-(1,3-dioxolan-2-yl)-2-methyl-3-thienyl]-3,4-dihydro-1H-isochromene (9.14 g, 30.2 mmol) in THF (117 mL) was added HCl (1 M aqueous solution, 117 mL, 117 mmol) at rt and the reaction was stirred for 1 h. The reaction was quenched by addition of saturated aqueous NaHCO3 and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (20% EtOAc in hexane) to give 7.36 g (94%) of the title compound as a pale yellow oil. 1H NMR (400 MHz, Chloroform-d) δ 9.71 (s, 1H), 7.39 (s, 1H), 7.25 - 7.09 (m, 3H), 6.73 (d, J = 7.7 Hz, 1H), 5.84 (s, 1H), 4.19 (ddd, J = 11.4, 5.5, 3.7 Hz, 1H), 3.94 (ddd, J = 11.4, 9.7, 4.0 Hz, 1H), 3.14 (ddd, J = 15.8, 9.7, 5.8 Hz, 1H), 2.83 (dt, J = 16.4, 3.7 Hz, 1H), 2.57 (s, 3H); LCMS (FA) m/z = 259.1 (M+H).
A solution of 4-chloro-5-iodopyrimidine (8.22 g, 34.2 mmol) in THF (200 mL) was cooled at -78 °C. To the solution was added 2.50 M of n-BuLi in hexane (27.4 mL, 68.4 mmol) at the same temperature. After stirring for 10 min, a solution of 4-[(1R)-3,4-dihydro-1H-isochromen-1-yl]-5-methylthiophene-2-carbaldehyde (7.36 g, 28.5 mmol) in THF (33.4 mL) was added at -78 °C, and the resulting mixture was stirred for 10 min at the same temperature. The reaction was quenched by addition of water and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (0 to 50% EtOAc in hexane) to give 10.1 g (95%) of the title compound mixture as a pale yellow amorphous solid. 1H NMR (400 MHz, Chloroform-d) δ 8.96 (s, 0.5H), 8.93 (s, 0.5H), 8.92 (s, 0.5H), 8.91 (s, 0.5H), 7.22 - 7.04 (m, 3H), 6.72 - 6.62 (m, 2H), 6.16 (s, 0.5H), 6.13 (s, 0.5H), 5.73 (s, 1H), 4.24 - 4.15 (m, 1H), 3.97 - 3.85 (m, 1H), 3.21 - 3.06 (m, 1H), 2.81 - 2.70 (m, 1H), 2.67 - 2.48 (br s, 1H), 2.43 (s, 1.5H), 2.41 (s, 1.5H); LCMS (FA) m/z = 373.1 (M+H).
To a solution of the product mixture from step 7 (10.1 g, 27.2 mmol) in DCM (363 mL) was added MnO2 (23.6 g, 272 mmol) at rt, and the reaction was stirred for 20 h. The reaction was filtered through a Celite pad and the residual solid was rinsed with DCM several times. The filtrate was concentrated in vacuo and the residue was purified by silica gel column chromatography (0 to 40% EtOAc in hexanes) to give 9.15 g (91%) of the title compound as an off-white amorphous solid. 1H NMR (400 MHz, Chloroform-d) δ 9.06 (s, 1H), 8.69 (s, 1H), 7.23 - 7.07 (m, 4H), 6.68 (d, J = 7.7 Hz, 1H), 5.79 (s, 1H), 4.19 (ddd, J = 11.4, 5.8, 3.0 Hz, 1H), 3.92 (dt, J = 10.9, 3.8 Hz, 1H), 3.13 (ddd, J = 16.1, 10.2, 5.8 Hz, 1H), 2.82 - 2.72 (m, 1H), 2.56 (s, 3H); LCMS (FA) m/z = 371.1 (M+H).
To a solution of (4-chloropyrimidin-5-yl){4-[(1R)-3,4-dihydro-1H-isochromen-1-yl)-5-methyl-2-thienyl}methanone (8.59 g, 23.2 mmol) in DMF (102 mL) was added Int-259 (7.99 g, 27.8 mmol) and K2CO3 (9.60 g, 69.5 mmol) at rt. After stirring for 21 h at rt, the reaction was concentrated in vacuo and the residue was diluted with water and EtOAc. The layers were separated and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (0 to 50% EtOAc in hexanes) to give 13.0 g (90%) of the title compound as a light yellow amorphous solid. 1H NMR (400 MHz, Chloroform-d) δ 8.73 - 8.63 (m, 2H), 8.60 (s, 1H), 7.24 (s, 1H), 7.22 - 7.14 (m, 2H), 7.13 - 7.07 (m, 1H), 6.69 (d, J = 7.7 Hz, 1H), 5.81 (s, 1H), 4.85 - 4.71 (m, 1H), 4.35 - 4.27 (m, 1H), 4.23 (ddd, J = 11.4, 5.7, 2.9 Hz, 1H), 3.94 (dt, J = 10.9, 3.7 Hz, 1H), 3.75 - 3.61 (m, 2H), 3.17 (ddd, J = 16.1, 10.3, 5.8 Hz, 1H), 2.83 - 2.73 (m, 1H), 2.55 (s, 3H), 2.48 (dt, J = 13.2, 8.0 Hz, 1H), 2.16 (ddd, J = 12.5, 8.0, 3.9 Hz, 2H), 1.88 - 1.76 (m, 1H), 1.74 - 1.66 (m, 1H), 1.35 - 1.23 (m, 1H), 1.06 (s, 21H); LCMS (FA) m/z = 622.3 (M+H).
A solution of (4-(((1R,3R,4S)-3-(hydroxymethyl)-4-((triisopropylsilyl)oxy)cyclopentyl)amino)pyrimidin-5-yl)(4-((R)-isochroman-1-yl)-5-methylthiophen-2-yl)methanone (13.0 g, 21.0 mmol) in DMF (102 mL) was cooled at 0 °C. Chlorosulfonamide (4.84 g, 41.9 mmol) was added to the solution and the mixture was stirred for 10 min at 0 °C. The reaction was quenched by addition of saturated NaHCO3 at 0 °C and diluted with EtOAc and water. The two layers were separated and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The obtained crude product was dissolved in THF (114 mL). To the solution was added HCl (4 N aqueous solution, 91.7 mL, 367 mmol) at rt. After stirring for 4 h, the reaction was cooled to 0 °C and quenched by addition of saturated aqueous NaHCO3. The resulting mixture was extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (0 to 6% MeOH in DCM) to afford 11.1 g (97% over two steps) of the title compound as a light yellow amorphous solid. The diastereomeric purity was determined to be 86% de by HPLC (70/30/0.1 hexane/EtOH/DEA; 1.0 mL/min for 60 min; using a CHIRALPAK ID column (4.6 × 250 mm)): 23.1 min (minor) and 31.7 min (major). 1H NMR (400 MHz, Methanol-d 4) δ 8.59 (s, 1H), 8.53 (s, 1H), 7.24 (s, 1H), 7.22 - 7.15 (m, 2H), 7.16 - 7.07 (m, 1H), 6.76 (d, J = 7.6 Hz, 1H), 5.93 (s, 1H), 4.83 - 4.70 (m, 1H), 4.24 - 4.10 (m, 4H), 4.01 - 3.89 (m, 1H), 3.16 - 3.03 (m, 1H), 2.87 - 2.76 (m, 1H), 2.54 (s, 3H), 2.52 - 2.43 (m, 1H), 2.31 - 2.19 (m, 1H), 2.13 (ddd, J = 12.7, 7.4, 4.2 Hz, 1H), 1.88 (dt, J = 13.6, 7.2 Hz, 1H), 1.40 (dt, J = 13.1, 9.1 Hz, 1H); LCMS (FA) m/z = 545.2 (M+H).
A solution of bromide Int-1 (19.4 g, 77.9 mmol) in THF (200.0 mL) was cooled to -78 °C. 2.50 M of n-BuLi in hexane (33.5 mL, 83.8 mmol) was added and the mixture was stirred for 10 min at -78 °C. After stirring for 10 min, a solution of aldehyde Int-15 (17.9 g, 59.9 mmol) in THF (50.0 mL) was added and the reaction was stirred at -78 °C for 10 min. The reaction was quenched by adding brine (150 mL) and then warmed to rt. Layers were separated, and the organic layer was washed 3 x brine, then dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified by flash column chromatography eluting with a hexane:EtOAc gradient to afford the title compound (22.0 g, 78%). 1H NMR (400 MHz, Chloroform-d) δ 7.39 (d, J = 2.2 Hz, 1H), 6.99 (s, 1H), 6.06 (d, J = 2.6 Hz, 1H), 6.03 (s, 1H), 4.22 - 4.13 (m, 3H), 4.07 - 4.01 (m, 2H), 3.91 - 3.84 (m, 1H), 3.79 - 3.71 (m, 1H), 3.27 (d, J = 2.9 Hz, 1H), 2.96 (ddd, J = 14.4, 8.3, 6.1 Hz, 1H), 2.82 - 2.73 (m, 1H), 2.43 (s, 3H), 0.88 (s, 10H), 0.01 (d, J = 4.5 Hz, 6H).
To a solution of [2-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-5-chlorophenyl][5-(1,3-dioxolan-2-yl)-2-methyl-3-thienyl]methanol (22.0 g, 46.9 mmol) in DCM (250 mL) was added MnO2 (40.8 g, 469 mmol) at rt and the reaction was stirred for 13 h. Added MnO2 (40.8 g, 469 mmol), and then reaction was mechanically shaken at rt for 13 h. The reaction was filtered through a Celite pad and the residual solid was rinsed with EtOAc (1 L). The filtrate was concentrated in vacuo and the residue was purified by silica gel column chromatography (5% EtOAc in hexane) to give 22.9 g (77%) of the title compound as a colorless solid. 1H NMR (400 MHz, DMSO-d6) δ 7.62 (dd, J = 8.3, 2.3 Hz, 1H), 7.53 (d, J = 8.3 Hz, 1H), 7.47 (d, J = 2.3 Hz, 1H), 7.11 (s, 1H), 6.04 (s, 1H), 4.13 - 4.06 (m, 2H), 4.05 - 3.98 (m, 2H), 3.76 (t, J = 6.9 Hz, 2H), 2.83 (t, J = 6.9 Hz, 2H), 2.69 (s, 3H), 0.88 (s, 9H), -0.00 (s, 6H).
To a solution of [2-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-5-chlorophenyl][5-(1,3-dioxolan-2-yl)-2-methyl-3-thienyl]methanone (15.9 g, 34.0 mmol) in THF (477 mL) was added 0.5 M of (S)-(-)-o-tolyl-CBS-oxazaborolidine in toluene (34.0 mL, 17.0 mmol), followed by 1.00 M of BH3-THF complex in THF (37.4 mL, 37.4 mmol) at rt. After stirring for 1 h at rt, the reaction was quenched by addition of MeOH. The mixture was stirred for 25 min, and then the volatiles were removed in vacuo. The residue was dissolved in EtOAc and water and the aqueous layer was extracted with EtOAc. The combined organic layer was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (10 to 30% EtOAc in hexane) to give 15.3 g (90%) of (R)-[2-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-5-chlorophenyl][5-(1,3-dioxolan-2-yl)-2-methyl-3-thienyl]methanol. The crude alcohol was dissolved in THF (200 mL) and TBAF hydrate (10.9 g, 39.0 mmol) was added to the solution. After stirring for 10 min at 40 °C, the reaction was concentrated in vacuo. To the residue was added water and the mixture was extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (30 to 80% EtOAc in hexane) to give 9.9 g of the title compound as a colorless oil. 1H NMR (400 MHz, DMSO-d6) δ 7.55 (d, J = 2.2 Hz, 1H), 7.25 (dd, J = 8.2, 2.3 Hz, 1H), 7.19 (d, J = 8.2 Hz, 1H), 6.68 (s, 1H), 5.92 - 5.82 (m, 2H), 5.78 (d, J = 4.6 Hz, 1H), 4.69 (t, J = 5.1 Hz, 1H), 4.01 - 3.92 (m, 2H), 3.91 - 3.82 (m, 2H), 3.42 (dt, J = 13.1, 7.4 Hz, 2H), 2.65 - 2.53 (m, 2H), 2.43 (s, 3H).
To a solution of 2-[4-chloro-2-[(R)-[5-(1,3-dioxolan-2-yl)-2-methyl-3-thienyl]-hydroxymethyl]phenyl]ethanol (9.90 g, 27.9 mmol) in benzene (327 mL) were added pyridine (6.83 mL, 84.5 mmol) and PPh3 (9.90 g, 27.9 mmol), followed by I2 (7.43 g, 29.3 mmol). After stirring overnight at rt, the reaction mixture was filtered and the filter cake was rinsed with Et2O. To the filtrate was added water and hexane, the layers were separated, and the aqueous layer was extracted with hexane. The combined organic layers were washed with brine, then dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (10 to 20% EtOAc in hexane) to afford 13 g (99%) of the title compound as a pale yellow solid. LCMS (FA) m/z = 465.2 (M+H)
To a solution of (R)-[5-chloro-2-(2-iodoethyl)phenyl]-[5-(1,3-dioxolan-2-yl)-2-methyl-3-thienyl]methanol (13.0 g, 28.0 mmol) in Et2O (433 mL) was added silver(I) oxide (32.4 g, 140 mmol) and the reaction was stirred for two days at rt. The reaction was filtered through a Celite pad and the residual solid was rinsed with Et2O several times. The filtrate was concentrated in vacuo and the residue was purified by silica gel column chromatography (30% EtOAc in hexane) to give 8.4g (89%) of the title compound as a colorless oil. 1H NMR (400 MHz, DMSO-d6) δ 7.25 (s, 2H), 6.72 (s, 1H), 6.65 (s, 1H), 5.88 (s, 1H), 5.79 (s, 1H), 4.07 (ddd, J = 11.3, 5.5, 3.4 Hz, 1H), 4.02 - 3.95 (m, 2H), 3.92 - 3.86 (m, 2H), 3.86 - 3.77 (m, 1H), 3.05 - 2.92 (m, 1H), 2.76 (d, J = 16.5 Hz, 1H), 2.43 (s, 3H).
To a solution of (1R)-7-chloro-1-[5-(1,3-dioxolan-2-yl)-2-methyl-3-thienyl]isochromane (8.40 g, 24.9 mmol) in THF (96.6 mL) was added HCl (1 M aqueous solution, 96.6 mL, 96.6 mmol) at rt and the reaction was stirred for 1 h. The reaction was quenched by addition of saturated aqueous NaHCO3 and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (20% EtOAc in hexane) to give 7.15 g (98%) of the title compound. 1H NMR (400 MHz, DMSO-d6) δ 9.75 (s, 1H), 7.58 (s, 1H), 7.29 (d, J = 1.1 Hz, 2H), 6.74 (s, 1H), 5.92 (s, 1H), 4.12 - 4.02 (m, 1H), 3.90 - 3.79 (m, 1H), 3.07 - 2.94 (m, 1H), 2.85 - 2.75 (m, 1H), 2.55 (s, 3H).
A solution of 4-chloro-5-iodopyrimidine (7.05 g, 29.3 mmol) in THF (100 mL) was cooled at -78 °C. To the solution was added 2.50 M of n-BuLi in hexane (23.4 mL, 58.6 mmol) at the same temperature. After stirring for 10 min, a solution of 4-[(1R)-7-chloroisochroman-1-yl]-5-methylthiophene-2-carbaldehyde (7.15 g, 24.4 mmol) in THF (28.6 mL) was added at -78 °C, and the resulting mixture was stirred for 10 min at the same temperature. The reaction was quenched by addition of water and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (0 to 50% EtOAc in hexane) to give 9.34 g (94%) of the title compound mixture. 1H NMR (400 MHz, DMSO-d6) δ 8.99 (s, 1H), 8.94 (d, J = 3.1 Hz, 1H), 7.23 (d, J = 2.6 Hz, 2H), 6.67 (d, J = 4.6 Hz, 1H), 6.61 (d, J = 6.9 Hz, 1H), 6.53 (d, J = 5.5 Hz, 1H), 6.02 (dd, J = 8.1, 4.6 Hz, 1H), 5.74 (s, 1H), 4.11 - 4.04 (m, 1H), 3.84 - 3.74 (m, 1H), 3.02 - 2.92 (m, 1H), 2.73 (d, J = 16.6 Hz, 1H), 2.37 (s, 2H), 2.36 (s, 1H).
To a solution of the product mixture from step 7 (9.34 g, 22.9 mmol) in DCM (306 mL) was added MnO2 (19.9 g, 229 mmol) at rt, and the reaction was stirred for 20 h. The reaction was filtered through a Celite pad and the residual solid was rinsed with DCM several times. The filtrate was concentrated in vacuo and the residue was purified by silica gel column chromatography (0 to 40% EtOAc in hexane) to give 9.10 g (86%) of the title compound as an off-white amorphous solid. 1H NMR (400 MHz, DMSO-d6) δ 9.21 (s, 1H), 9.06 (s, 1H), 7.43 (s, 1H), 7.29 - 7.20 (m, 2H), 6.69 (s, 1H), 5.86 (s, 1H), 4.11 (ddd, J = 11.3, 5.7, 2.6 Hz, 1H), 3.87 - 3.75 (m, 1H), 3.07 - 2.94 (m, 1H), 2.74 (d, J = 16.6 Hz, 1H), 2.49 (s, 3H).
To a solution of [4-[(1R)-7-chloroisochroman-1-yl]-5-methyl-2-thienyl]-(4-chloropyrimidin-5-yl)methanone (8.01 g, 19.8 mmol) in iPrOH (274 mL) was added Int-259 (8.94 g, 31.1 mmol) and N,N-diisopropylethylamine (6.91 mL, 39.7 mmol) and the reaction was heated with stirring at 60 °C for 2 h. The reaction was concentrated in vacuo and the residue was purified by silica gel column chromatography (0 to 50% EtOAc in hexane) to give 12.5 g (96%) of the title product. 1H NMR (400 MHz, DMSO-d6) δ 8.58 (d, J = 5.9 Hz, 2H), 8.23 (d, J = 7.6 Hz, 1H), 7.34 (s, 1H), 7.28 - 7.22 (m, 2H), 6.74 (s, 1H), 5.90 (s, 1H), 4.70 - 4.64 (m, 2H), 4.23 (d, J = 5.5 Hz, 1H), 4.15 - 4.07 (m, 1H), 3.87 - 3.77 (m, 1H), 3.42 - 3.35 (m, 2H), 3.01 (t, J = 10.2 Hz, 1H), 2.76 (d, J = 16.8 Hz, 1H), 2.47 (s, 3H), 2.34 - 2.23 (m, 1H), 1.98 - 1.90 (m, 2H), 1.79 - 1.71 (m, 1H), 1.24 (dd, J = 13.1, 7.7 Hz, 1H), 1.03 (d, J = 2.0 Hz, 21H).
To a solution of [4-[(1R)-7-chloroisochroman-1-yl]-5-methyl-2-thienyl]-[4-[[(1R,3R,4S)-3-(hydroxymethyl)-4-triisopropylsilyloxy-cyclopentyl]amino]pyrimidin-5-yl]methanone (12.4 g, 18.9 mmol) in DMF (186 mL) was added triethylamine (18.4 mL, 132 mmol) followed by chlorosulfonamide (10.9 g, 94.5 mmol) and the reaction was stirred at rt for 1 h. The reaction mixture was placed in an ice bath, and then 6.0 M of HCl in water (271 mL) was added, followed by DMF (300 mL) and the reaction was stirred at rt for 2 h. The reaction was quenched via addition of concentrated aqueous NaOH until pH 9. Reaction mixture was partitioned between water (100 mL more) and EtOAc (400 mL). Sodium chloride was added to saturate the aqueous layer and aid separation of layers. Layers were separated, and the aqueous layer was extracted 2 x EtOAc (250 mL each). Combined organic layers were washed 3 x brine, then dried over Na2SO4, filtered, and concentrated in vacuo. Crude residue was purified by silica gel column chromatography (0 to 10% MeOH in DCM) to afford 10.5 g (96% over two steps) of the title compound as an off-white amorphous solid. 1H NMR (400 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.59 (s, 1H), 8.19 (d, J = 7.5 Hz, 1H), 7.44 (s, 2H), 7.36 (s, 1H), 7.26 (d, J = 1.8 Hz, 2H), 6.75 (s, 1H), 5.91 (s, 1H), 4.88 (d, J = 4.6 Hz, 1H), 4.69 (q, J = 8.1 Hz, 1H), 4.17 - 4.05 (m, 2H), 3.96 (dd, J = 9.5, 7.1 Hz, 2H), 3.88 - 3.79 (m, 1H), 3.08 - 2.96 (m, 1H), 2.79 (s, 1H), 2.48 (s, 3H), 2.36 - 2.24 (m, 1H), 2.11 (d, J = 5.8 Hz, 1H), 1.99 - 1.89 (m, 1H), 1.80 - 1.70 (m, 1H), 1.33 - 1.21 (m, 1H). LCMS (FA) m/z = 579.1 (M+H).
An oven-dried 2-neck 250 mL round bottom flask under nitrogen was charged with THF (40 mL) and cooled to -74 °C. Added 2.50 M n-BuLi in hexane (6.92 mL, 17.3 mmol). Added a solution of Int-1 (4.00 g, 16.0 mmol) in THF (60 mL) slowly keeping the internal temperature less than -70 °C. Stirred with cooling 5 min. A second oven-dried 250 mL round bottom flask under nitrogen was charged with THF (60 mL) and Int-50 (2.04 g, 12.4 mmol) and the resulting solution was cooled to 0 °C. Added boron trifluoride diethyl ether complex (1.71 mL, 13.6 mmol) slowly and cooled to -30 °C . The contents of the first flask were transferred via cannula to the second flask. Reaction was quenched with saturated aqueous NaHCO3 and warmed to rt. Water was added, and the mixture was extracted three times with EtOAc. Combined organic portions were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. Residue was purified via flash column chromatography eluting with a hexane / EtOAc gradient (0 to 100% EtOAc) to afford the title compound as a white solid (1.88g, 45%). 1H NMR (400 MHz, Chloroform-d) δ 7.17 - 7.01 (m, 2H), 6.83 - 6.61 (m, 2H), 5.92 (s, 1H), 5.09 (s, 1H), 4.17 - 4.04 (m, 2H), 4.03 - 3.92 (m, 2H), 3.37 - 3.25 (m, 1H), 3.13 - 2.91 (m, 2H), 2.82 - 2.69 (m, 1H), 2.46 (s, 3H). LCMS: (AA) M+1 336.1
A 50 mL round bottom flask under nitrogen was charged with 7-chloro-1-[5-(1,3-dioxolan-2-yl)-2-methyl-3-thienyl]-1,2,3,4-tetrahydroisoquinoline (5.67 g, 16.9 mmol) and DCM (100 mL), to which was added triethylamine (4.71 mL, 33.8 mmol), di-tert-butyldicarbonate (4.61 g, 21.1 mmol), and N,N-dimethylaminopyridine (23 mg, 0.18 mmol). Reaction was stirred for 1 h at rt and then poured into saturated NaHCO3 solution. Mixture was extracted three times with DCM, and the combined organic portions were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was subjected to flash column chromatography eluting with a hexane / EtOAc gradient to afford 6.96g (95%) of the title compound. LCMS: (AA) M+1 436.1
A 1 L round bottom flask was charged with tert-butyl 7-chloro-1-[5-(1,3-dioxolan-2-yl)-2-methyl-3-thienyl]-3,4-dihydroisoquinoline-2(1H)-carboxylate (7.30 g, 16.7 mmol), methanol (200 mL), and water (20 mL), to which was added a solution of 12M HCl (4.00 mL, 130 mmol) in methanol (200 mL), and the reaction was stirred at rt for 1 h. Reaction was quenched via addition of 50mL of saturated NaHCO3 and stirred for 5 min. Methanol was removed in vacuo, and the resulting aqueous mixture was extracted three times with EtOAc, and then the combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was subjected to flash column chromatography eluting with a hexane / EtOAc gradient to afford the title compound (4.55g, 70%). 1H NMR (400 MHz, Chloroform-d) δ 9.67 (s, 1H), 7.27 - 7.15 (m, 2H), 7.12 (s, 1H), 6.98 - 6.94 (m, 1H), 6.34 (m, 1H), 4.15 (s, 1H), 3.18 - 3.06 (m, 1H), 3.05 - 2.93 (m, 1H), 2.82 - 2.73 (m, 1H), 2.69 (s, 3H), 1.50 (s, 9H). LCMS: (AA) M+Na 414.2
An oven-dried 500 mL 3-neck round bottom flask under nitrogen was charged with 4-chloro-5-iodopyrimidine (4.08 g, 17.0 mmol) and 2-methyltetrahydrofuran (150 mL). An addition funnel containing a solution of tert-butyl 7-chloro-1-(5-formyl-2-methyl-3-thienyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (4.75 g, 12.1 mmol) in 2-methyltetrahydrofuran (50 mL) was attached, and the contents of the reaction flask were cooled to -75 °C. 2.50 M n-BuLi in hexane (14.1 mL, 35.2 mmol) was added in small portions keeping the internal temperature less than -70 °C , at which point the contents of addtion funnel were added in a single portion. Upon completion of addition, the reaction was quenched by adding 20 mL of saturated NaHCO3 in small portions and warmed to rt. The aqueous mixture was extracted three times with EtOAc, and then the combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was subjected to flash column chromatography eluting with a hexane / EtOAc gradient to afford the title compound (4.85g, 79%). LCMS: (AA) M+Na 528.1
A 1L round bottom flask was charged with tert-butyl 7-chloro-1-{5-[(4-chloropyrimidin-5-yl)(hydroxy)methyl]-2-methyl-3-thienyl}-3,4-dihydroisoquinoline-2(1H)-carboxylate (4.85 g, 9.58 mmol) and DCM (300 mL). Manganese (IV) oxide (14.2 g, 163 mmol) was added and the reaction was stirred at rt for 18 h. Mixture was filtered through Celite, and the filter cake was rinsed with hot EtOAc. Filtrate was concentrated in vacuo to afford the title compound (4.47g , 93%). 1H NMR (400 MHz, Chloroform-d) δ 9.09 (s, 1H), 8.70 (s, 1H), 7.24 - 7.16 (m, 1H), 7.16 - 7.07 (m, 1H), 7.00 - 6.90 (m, 2H), 6.32 (s, 1H), 4.28 - 3.97 (m, 1H), 3.14 - 2.89 (m, 2H), 2.78 - 2.65 (m, 4H), 1.53 - 1.43 (m, 9H).
A 1L round bottom flask under nitrogen was charged with tert-butyl 7-chloro-1-{5-[(4-chloropyrimidin-5-yl)carbonyl]-2-methyl-3-thienyl}-3,4-dihydroisoquinoline-2(1H)-carboxylate (4.47 g, 8.86 mmol), DMF (20.0 mL, 258 mmol), Int-259 (3.06 g, 10.6 mmol), and triethylamine (3.09 mL, 22.2 mmol) and the mixture was stirred at rt for 18 h. Reaction mixture was poured into water and saturated NaHCO3, and then extracted three times with EtOAc, and then the combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was subjected to flash column chromatography eluting with a 70/30 to 60/40 hexane/EtOAc gradient to afford 0.56g of first-eluting diastereomer 1 (not pictured), 4.31g of a mixture of diastereomers, and 1.11g (17%) of second-eluting diastereomer 2 (the title compound). The mixture of diastereomers thus obtained was resubjected to the described chromatography conditions two additional times to afford a total of 2.62 g of the desired diastereomer. 1H NMR (400 MHz, Methanol-d4) δ 8.54 - 8.46 (m, 2H), 7.27 - 7.19 (m, 2H), 7.09 - 6.99 (m, 2H), 6.37 (s, 1H), 4.87 - 4.75 (m, 1H), 4.38 - 4.29 (m, 1H), 4.20 - 4.09 (m, 1H), 3.66 - 3.52 (m, 2H), 3.28-3.14 (m, 2H), 3.02 - 2.89 (m, 1H), 2.89 - 2.78 (m, 1H), 2.68 (s, 3H), 2.54 - 2.41 (m, 1H), 2.22 - 2.09 (m, 2H), 1.86 - 1.73 (m, 1H), 1.50 (s, 8H), 1.39 - 1.23 (m, 2H), 1.15 - 1.04 (m, 20H). LCMS: (AA) M+1 755.3
A solution of tert-butyl (1R)-7-chloro-1-[5-[4-[[(1R,3R,4S)-3-(hydroxymethyl)-4-triisopropylsilyloxy-cyclopentyl]amino]pyrimidine-5-carbonyl]-2-methyl-3-thienyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (2.46 g, 3.26 mmol) in 2-methyltetrahydrofuran (25 mL), and DMF (25 mL) was cooled to 0 °C. Triethylamine (1.82 mL, 13.0 mmol) and chlorosulfonamide (1.50 g, 13.0 mmol) were added and the reaction was stirred for 10 min. Added methanol (0.53 mL, 13.0 mmol) and stirred for 15 min. Reaction mixture was poured into saturated NaHCO3, extracted three times with EtOAc, and then the combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was subjected to flash column chromatography eluting with a hexane / EtOAc gradient to afford the title compound (2.41g, 89%). 1H NMR (400 MHz, Methanol-d4) δ 8.58 - 8.45 (m, 2H), 7.29 - 7.17 (m, 2H), 7.11 - 6.98 (m, 2H), 6.36 (s, 1H), 4.84 - 4.73 (m, 1H), 4.44 - 4.33 (m, 1H), 4.21 - 4.08 (m, 4H), 3.27-3.17 (m, 1H),3.02 - 2.89 (m, 1H), 2.88 - 2.78 (m, 1H), 2.67 (s, 3H), 2.57 - 2.47 (m, 1H), 2.41 - 2.30 (m, 1H), 2.23 - 2.13 (m, 1H), 1.87-1.78 (m, 1H), 1.50 (s, 9H), 1.43 - 1.33 (m, 1H), 1.17 - 1.04 (m, 20H). LCMS: (AA) M+1 834.3
A solution of tert-butyl (1R)-7-chloro-1-[2-methyl-5-[4-[[(1R,3R,4S)-3-(sulfamoyloxymethyl)-4-triisopropylsilyloxy-cyclopentyl]amino]pyrimidine-5-carbonyl]-3-thienyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (2.41 g, 2.89 mmol) in CH3CN (10 mL) was cooled in an ice bath to +1 °C. Phosphoric acid (10 mL, 200 mmol) was added dropwise and the reaction was stirred with ice bath cooling for 60 min. The mixture was warmed to rt and stirred for an additional 3 h. Reaction was poured into a stirring mixture of 50 mL water and 50 mL EtOAc, and the the pH was adjusted to ∼9 by slowly adding 200 mL of saturated NaHCO3 with stirring. Resulting aqueous mixture was extracted three times with EtOAc, and then the combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was subjected to flash column chromatography eluting with a gradient that began with 100% DCM and increased in polarity to 80% DCM / 20% methanol / 2% ammonium hydroxide gradient to afford the title compound (1.50 g, 90%). 1H NMR (400 MHz, Methanol-d4) δ 8.61 (s, 1H), 8.52 (s, 1H), 7.27 (s, 1H), 7.18 - 7.13 (m, 2H), 6.73 - 6.68 (m, 1H), 5.23 (s, 1H), 4.81 - 4.70 (m, 1H), 4.26 - 4.10 (m, 3H), 3.29 - 3.23 (m, 2H), 3.11 - 2.96 (m, 2H), 2.87 - 2.76 (m, 1H), 2.60 (s, 3H), 2.55 - 2.42 (m, 1H), 2.33 - 2.19 (m, 1H), 2.18 - 2.07 (m, 1H), 1.95 -1.81 (m, 1H), 1.47 - 1.35 (m, 1H). LCMS: (AA) M+1 580.0
A solution of 4-chloro-5-iodopyrimidine (216 mg, 0.90 mmol) in THF (5.0 mL) was cooled to -78 °C with dry-ice bath. To the solution was added dropwise 2.50 M of n-BuLi in hexane (0.36 mL, 0.90 mmol) at -78 °C, and the mixture was stirred for 20 min. To the mixture was added a solution of Int-79 (210 mg, 0.75 mmol) in THF (2.0 mL) at -78 °C, and the resulting mixture was stirred for 30 min. The reaction was quenched by addition of saturated NH4Cl (50mL) and extracted with EtOAc (50mLx3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. Residue was subjected to flash column chromatography eluting with a hexanes / EtOAc gradient to afford the title compound as a colorless oil (yield = 260 mg). 1H NMR (400 MHz, Chloroform-d) δ 9.02 (s, 1H), 8.94 (s, 1H), 7.35 (d, J = 7.9 Hz, 1H), 7.32 (s, 1H), 7.17 (t, J = 7.7 Hz, 1H), 7.09 (d, J = 7.7 Hz, 1H), 6.91 (s, 1H), 6.82 (s, 1H), 6.27 (s, 1H), 3.86 (s, 2H), 2.86 - 2.60 (br s, 1H).
To a solution of rac-[4-(3-bromobenzyl)-2-thienyl](4-chloropyrimidin-5-yl)methanol (255 mg, 0.64 mmol) in DCM (10.0 mL) was added Dess-Martin periodinane (410 mg, 0.97 mmol) at rt, and the mixture was stirred for 15 min. The reaction was quenched by addition of saturated NaHCO3 (50mL) and extracted with DCM (50mLx3). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography eluting with a hexanes / EtOAc gradient to afford the title compound as a colorless oil (yield = 247 mg). 1H NMR (400 MHz, Chloroform-d) δ 9.12 (s, 1H), 8.75 (s, 1H), 7.49 - 7.45 (m, 1H), 7.38 (d, J = 8.0 Hz, 1H), 7.31 (s, 1H), 7.28 (d, J = 1.4 Hz, 1H), 7.18 (t, J = 7.8 Hz, 1H), 7.09 (d, J = 7.7 Hz, 1H), 3.94 (s, 2H).
To a mixture of [4-(3-Bromobenzyl)-2-thienyl](4-chloropyrimidin-5-yl)methanone (105 mg, 0.27 mmol) and [(3aR,4R,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methanol hydrochloride (65.6 mg, 0.29 mmol) (for synthesis of this starting material see: Claiborne, C.F. et al. PCT Application Publication WO2008/019124 ) in i-PrOH (2.2 mL) was added N,N-diisopropylethylamine (0.14 mL, 0.80 mmol). The resulting mixture was stirred at 50 °C for 4 h. After cooling to rt, the reaction was concentrated in vacuo. Subjected to ISCO chromatography eluting with a hexanes / EtOAc gradient to afford the title compound as a white solid (yield = 127 mg). LCMS (FA): m/z = 546.2 (M+H)
To a solution of [4-(3-bromobenzyl)-2-thienyl](4-{[(3aS,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]amino}pyrimidin-5-yl)methanone (125 mg, 0.23 mmol) in DMF (3.6 mL) and triethylamine (0.08 mL, 0.56 mmol) was added chlorosulfonamide (66.3 mg, 0.57 mmol) at rt, and the mixture was stirred for 2 h. The reaction was quenched with saturated NaHCO3 end the mixture was extracted with EtOAc (x3). The combined organic layers were then dried using MgSO4, filtered and concentrated in vacuo to yield 140 mg of the crude title compound. LCMS (FA): m/z = 625.2 (M+H)
To a solution of {(3aR,4R,6R,6aS)-6-[(5-{[4-(3-bromobenzyl)-2-thienyl]carbonyl}pyrimidin-4-yl)amino]-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl}methyl sulfamate (0.14 g, 0.22 mmol) in THF (1.6 mL) was added water (1.6 mL) and 12 M of HCl (0.28 mL, 3.37 mmol) at rt, and the mixture was stirred at rt for 45 min. The reaction was quenched by addition of saturated NaHCO3 and water and extracted with EtOAc (50 mLx4). The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude mixture was purified by preparative HPLC to yield 57 mg of the title compound. 1H NMR (400 MHz, DMSO-d 6) δ 8.70 (s, 1H), 8.63 (s, 1H), 8.35 (d, J = 7.6 Hz, 1H), 7.82 (d, J = 1.2 Hz, 1H), 7.71 (d, J = 1.3 Hz, 1H), 7.51 (d, J = 1.6 Hz, 1H), 7.45 (s, 2H), 7.40 (dt, J = 7.4, 1.7 Hz, 1H), 7.32 - 7.23 (m, 2H), 4.87 (d, J = 5.9 Hz, 1H), 4.72 (d, J = 4.8 Hz, 1H), 4.50 - 4.40 (m, 1H), 4.06 (dd, J = 9.7, 6.2 Hz, 1H), 4.00 (s, 2H), 3.96 (dd, J = 9.7, 6.7 Hz, 1H), 3.82 - 3.74 (m, 1H), 3.72 - 3.66 (m, 1H), 2.32 - 2.23 (m, 1H), 2.23 - 2.12 (m, 1H), 1.14 (dt, J = 12.7, 8.7 Hz, 1H). LCMS (FA): m/z = 585.3 (M+H)
To a solution of 4-chloro-5-iodopyrimidine (1.06 g, 4.39 mmol) in THF (60.0 mL) was added 2.50 M of n-BuLi in hexane (3.92 mL, 9.81 mmol) at -78 °C under atmosphere of argon and the mixture was stirred for 15 min. To the mixture was added Int-120 (1.00 g, 3.99 mmol) as a solution in THF (10.0 mL, 123 mmol) at -78 °C and the reaction was allowed to stir at -78 °C for 30 min. The reaction mixture was quenched by addition of a solution of AcOH (0.60 g, 9.97 mmol) in THF (15 mL) and the solution was warmed to rt. Water was added and the mixture extracted with EtOAc (x3). The combined the organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by ISCO column chromatography (0% - 50% EtOAc in hexanes as eluent) to give 1.14g (78 %) of the title compound. LCMS (FA): m/z = 366.9 (M+H).
To a solution of [5-(3-chlorobenzyl)-3-methyl-2-thienyl](4-chloropyrimidin-5-yl)methanol (243 mg, 0.67 mmol) in DCM (30 mL) was added MnO2 (578 mg, 6.65 mmol) and the mixture was stirred for 19 h at rt. The reaction was filtered through a Celite pad and the residual solid was washed with DCM several times. The filtrate was concentrated in vacuo. The residue was purified by ISCO column chromatography (0-50% EtOAc in hexanes as eluent) to give 182 mg (75 %) of the title compound as white solid. 1H NMR (400 MHz, Chloroform-d) δ 9.13 (s, 1H), 8.75 (s, 1H), 7.37 - 7.28 (m, 2H), 7.19 - 7.13 (m, 1H), 6.84 (s, 1H), 4.14 (s, 2H), 2.51 (s, 3H).
To a solution of {(1R,2S,4R)-4-amino-2-[(triisopropylsilyl)oxy]cyclopentyl}methanol (Int-259, 46 mg, 0.16 mmol) in i-PrOH (8.0 mL) was added N,N-diisopropylethylamine (0.17 mL, 0.95 mmol) followed by [5-(3-chlorobenzyl)-3-methyl-2-thienyl](4-chloropyrimidin-5-yl)methanone (71.5 mg, 0.20 mmol), and the reaction was stirred at 50 °C for 1 hour. The reaction was concentrated in vacuo and the residue was purified by ISCO column chromatography (0% - 60% EtOAc in hexanes as eluent) to give 36.1 mg (37 %) of the title compound. LCMS (FA): m/z = 614.3 (M+H).
To a solution of [5-(3-chlorobenzyl)-3-methyl-2-thienyl][4-({(1R,3R,4S)-3-(hydroxymethyl)-4-[(triisopropylsilyl)oxy]cyclopentyl}amino)pyrimidin-5-yl]methanone (51.1 mg, 0.08 mmol) in THF (8.0 mL) was added N,N-diisopropylethylamine (58 uL, 0.33 mmol) followed by chlorosulfonamide (19.2 mg, 0.17 mmol) at 0 °C and the reaction was stirred for 30 min. The reaction was concentrated in vacuo and the residue was purified by ISCO column chromatography (10% - 60% EtOAc in hexanes as eluent) to give 38.7 mg (67 %) of the title compound. LCMS (FA): m/z = 693.3 (M+H).
{(1R,2S,4R)-4-[(5-{[5-(3-chlorobenzyl)-3-methyl-2-thienyl]carbonyl}pyrimidin-4-yl)amino]-2-[(triisopropylsilyl)oxy]cyclopentyl}methyl sulfamate (48.1 mg, 0.07 mmol) was dissolved into the solution of TFA (7.20 mL, 93.4 mmol) and water (0.80 mL, 44 mmol). The reaction was stirred at rt for 30 min. The reaction mixture was concentrated in vacuo, and the residue was diluted with MeOH (5 mL) and triethylamine (0.5 mL). After concentration of the mixture in vacuo, the residue was diluted with EtOAc (20 mL) and the mixture was washed with water (x2). The organic layer was dried over Na2SO4, filtered, and concentrated in vacuo. the residue was purified by ISCO column chromatography (0% - 10% MeOH in DCM as eluent) to give 28.3 mg (76 %) of the title compound. 1H NMR (400 MHz, Chloroform-d) δ 8.67 (s, 1H), 8.61 (s, 1H), 8.57 (d, J = 7.3 Hz, 1H), 7.29 - 7.20 (m, 3H), 7.12 (d, J = 6.6 Hz, 1H), 6.71 (s, 1H), 5.75 - 5.58 (br s, 2H), 4.81 - 4.69 (m, 1H), 4.38 - 4.28 (m, 2H), 4.23 (dd, J = 9.9, 5.8 Hz, 1H), 4.08 (s, 2H), 2.73 - 2.24 (m, 6H), 2.20 - 2.09 (m, 1H), 2.03 - 1.93 (m, 1H), 1.48 - 1.37 (m, 1H). LCMS (FA): m/z = 537.1 (M+H).
The compounds listed in the table below were prepared in an analogous fashion to that described above starting from the appropriate starting materials. The following alternative conditions were employed in the described reaction steps.
- Step 3: Base/solvent were A: N,N-diisopropylethylamine /i-PrOH, B: K2CO3/DMF, C: triethylamine,/DMF
- Step 4: Reaction was run A: Without triethylamine, B: With triethylamine
- Step 5: Desilylating agent/solvent were A: HCl/THF, B: TBAF/THF, C: TFA/water, D: H3PO4/CH3CN, E: TAS-F/DMF
| I-256 | ||
| I-257 | ||
| ** Diastereomers were resolved in step 3 by silica gel flash chromatography in analogous fashion to Example 133, step 6. |
The title compound was prepared in an analogous fashion to Example 131, step 7 beginning from Int-204. 1H NMR (400 MHz, Chloroform-d) δ 9.05 (s, 1H), 8.96 (s, 1H), 7.26 - 7.17 (m, 3H), 7.12 (s, 1H), 7.02 (s, 1H), 6.78 (s, 1H), 6.40 - 6.10 (m, 2H), 3.10 (s, 1H), 2.97 (s, 1H), 2.89 - 2.69 (m, 2H), 1.50 (s, 9H).
The title compound was prepared in an analogous fashion to Example 131, step 8. 1H NMR (400 MHz, Chloroform-d) δ 9.13 (s, 1H), 8.76 (s, 1H), 7.46 (s, 1H), 7.39 (s, 1H), 7.28 - 7.21 (m, 3H), 7.11 (d, J = 7.6 Hz, 1H), 6.36 (s, 1H), 3.12 (s, 1H), 3.06 - 2.91 (m, 1H), 2.76 (d, J = 16.0 Hz, 1H), 1.47 (s, 9H).
The title compound was prepared in an analogous fashion to Example 131, step 9. LCMS (FA): m/z = 708.1 (M+H)
The title compounds were prepared in an analogous fashion to Reference Example 134, step 4. LCMS (FA): m/z = 787.1 (M+H)
To a solution of the product mixture from Step 4 (391.57 mg, 0.49812 mmol) in THF (7.73 mL) was added a solution of TBAF hydrate (278.4 mg, 0.9962 mmol) in THF (7.73 mL, 95.3 mmol) at rt, and the mixture was stirred for 3h. The reaction was quenched by addition of water and extracted with EtOAc (x3). The combined orgnaic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by ISCO silica gel column chromatography (eluting with 0 to 90% EtOAc in Hexane) to give 245 mg of the title compound mixture as a light yellow amorphous solid LCMS (FA): m/z = 630.9 (M+H)
To a flask containing the product mixture from step 5 (245.0 mg, 0.3890 mmol) was added TFA (3.08 mL, 39.9 mmol) and the mixture was stirred at rt for 15 min. The mixture was concentrated in vacuo and small amount of saturated NaHCO3 was added to the residue. The resulting mixture was concentrated in vacuo and the residue was purified by ISCO silica gel column chromatography [eluting with 50% DCM in mixed solution of (2% NH4OH: 5% MeOH: 43% CH3CN in 50% DCM) for 3min then gradient to 100% of mixed solution (2% NH4OH: 5% MeOH: 43% CH3CN in 50% DCM)] to provide 196 mg of the title compound mixture as light yellow amorphous solid. 1H NMR (400 MHz, Methanol-d4) δ 8.73 (s, 1H), 8.57 (s, 1H), 7.67 (s, 1H), 7.58 (s, 1H), 7.19 (d, J = 3.9 Hz, 2H), 7.17 - 7.07 (m, 1H), 6.89 (d, J = 7.6 Hz, 1H), 5.32 (s, 1H), 4.83 - 4.73 (m, 1H), 4.26 - 4.11 (m, 3H), 3.26 - 3.16 (m, 1H), 3.15 - 2.90 (m, 3H), 2.56 - 2.45 (m, 1H), 2.33 - 2.21 (m, 1H), 2.22 - 2.09 (m, 1H), 1.95 - 1.85 (m, 1H), 1.49 - 1.36 (m, 1H); LCMS: (FA) M+1 530.4
The compounds listed in the table below were prepared in an analogous fashion to that described above starting from the appropriate starting materials. The following alternative conditions were employed in the described reaction steps.
- Step 3: Base/solvent were A: N,N-diisopropylethylamine /i-PrOH, B: K2CO3/DMF, C: triethylamine,/DMF
- Step 4: Reaction was run A: Without triethylamine, B: With triethylamine Final deprotection conditions were A: analogous to steps 5 and 6 above, B: Analogous to step 5, C: Analogous to step 5, using TFA/water as the deprotecting agent and solvent, D: Analogous to step 5, using H3PO4/CH3CN as the deprotecting agent and solvent E: Analogous to step 5, using HCl/MeOH as the deprotecting agent and solvent. When conditions B, C, D, or E were employed, step 6 was not peformed.
| I-263a** | ||
| I-263b** | ||
| ** Diastereomers were resolved in step 3 by silica gel flash chromatography in analogous fashion to Example 133, step 6. |
To a solution of 2-(4-bromo-5-methyl-2-thienyl)-1,3-dioxolane (90.3 g, 362 mmol) in THF (500 mL) was added dropwise 2.50 M of n-BuLi (193 mL, 483 mmol) at -78 °C under an atmosphere of N2, and the mixture was allowed to stir at -78°C for 20 min. Another reaction vessel was charged with 7-chloro-3,4-dihydroisoquinoline (40 g, 242 mmol) and the contents were dissolved in THF (1.3L). To this solution was added dropwise BF3-Et2O (32.8 mL, 265.7 mmol) at -30°C, and the solution was allowed to stir for 10 min. To this mixture was added dropwise the previous lithiated mixture via cannula and the resulting mixture was allowed to stir at -30°C for 30 min. Then the reaction mixture was allowed to warm to 0°C and stirred for 1 h. The reaction was quenched by addition of saturated aqueous NaHCO3, and the mixture was extracted with EtOAc (500 mL x 3). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The above procedure was perfomed on the same scale two additional times. The residues from all three procedures were then combined and purified by silica gel chromagraphy, eluting with a 85/15 to 0/100 pentane/EtOAc gradient to provide a yellow solid. The resulting solid was washed with pentane of to provide the racemic mixture (110 g, 45%) as a yellow solid. The racemic mixture was separated into the individual component enantiomers by chiral chromatography (SFC: CHIRALPAK AD 50x300mm with 35/65 0.1% NH4OH in MeOH/CO2, 200 mL/min, 10 MPa) to obtain 51.5 g (99.7% ee) of (1R)-7-chloro-1-[5-(1,3-dioxolan-2-yl)-2-methyl-3-thienyl]-1,2,3,4-tetrahydroisoquinoline as first elute (retention time 3.7 min, LCMS: (AA) M+1 336.0) and 50.0g (99.7% ee) of (1S)-7-chloro-1-[5-(1,3-dioxolan-2-yl)-2-methyl-3-thienyl]-1,2,3,4-tetrahydroisoquinoline as second elute (retention time 4.8 min, LCMS: (AA) M+1 336.0).
To a solution of (1R)-7-chloro-1-[5-(1,3-dioxolan-2-yl)-2-methyl-3-thienyl]-1,2,3,4-tetrahydroisoquinoline (48 g, 142 mmol) in DCM (700 mL) was added Boc2O (34 g, 156 mmol). The reaction was allowed to stir for 3 h at rt. The reaction mixture was filtered and concentrated in vacuo. Optionally, tert-butyl (R)-1-(5-(1,3-dioxolan-2-yl)-2-methylthiophen-3-yl)-7-chloro-3,4-dihydroisoquinoline-2(1H)-carboxylate may be isolated at this stage. The residue was dissolved in THF (720 mL) and 1.0 M of HCl in H2O (360 mL, 360 mmol) was added to the solution. The reaction was allowed to stir for 1 h at rt. The reaction mixture was quenched by addition of saturated aqueous NaHCO3 (600 mL) and concentrated in vacuo to remove THF. The resulting mixture was extracted with EtOAc (600 mL x 3). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The crude solid was purified by silica gel chromatography (330 g column, eluting with 95/5 to 85/15 pentane/EtOAc gradient) to provide 54 g (81%) of the title compound as a light yellow oil. 1H NMR (400 MHz, CHLOROFORM-d) δ 9.64 (s, 1 H) 7.06 - 7.24 (m, 3 H) 6.94 (s, 1 H) 6.30 (s, 1 H) 4.05 - 4.20 (m, 1 H) 3.07 - 3.13 (m, 1 H) 2.90 - 3.04 (m, 1 H) 2.70 - 2.78 (m, 1 H) 2.66 (s, 3 H) 1.50 (s, 9 H). The solvent may alternatively comprise any one or more of dichloromethane, THF, MeTHF, and tert-butyl methylether. The solvent or solvent system for the reaction with Boc2O may be the same as or different from the solvent or solvent system for the reaction with HCl.
A solution of 4-chloro-5-iodopyrimidine (27.85 g, 116 mmol) in THF (280 mL) was cooled to -78 °C with a dry-ice/MeOH bath. To the solution was added dropwise 2.50 M of n-BuLi in hexane (93 mL, 233 mmol) and the mixture was allowed to stir for 15 min at -78 °C. To the mixture was added dropwise a solution of tert-butyl (1R)-7-chloro-1-(5-formyl-2-methyl-3-thienyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate (27 g, 68.5 mmol) in THF (90 mL) at -75 °C, and the resulting mixture was allowed to stir for 10 min at -40°C followed by stirring for 30 min at 26 °C. The reaction was quenched by addition of saturated aqueous NH4Cl (560 mL) and extracted with EtOAc (600 mL x 3). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo to provide 90 g of a maroon oil which was used without further purification. This step can also be done using a magnesium-halogen exchange (such as isopropylmagnesium chloride lithium chloride complex). Solvent for this transformation can alternatively comprise MeTHF. This reaction also can be run at 0 °C to room temperature. The crude mixture was divided into three portions (30g, 59 mmol each) and each portion was dissolved in DCM (500 mL). Manganese (IV) oxide (86.7 g, 1 mol) was added to each solution and the reactions were allowed to stir at 30°C for 4 h, at which point they were combined and filtered through a Celite pad. The filter cake was rinsed with DCM/MeOH (100/1, 500 mL x 3). The filtrate was concentrated in vacuo and the residue was purified by column chromatography eluting with 90/10 to 85/15 pentane/EtOAc gradient to provide 40 g (58% in 2 steps) of the title compound as a light yellow solid. The oxidation of tert-butyl (1R)-7-chloro-1-(5-((4-chloropyrimidin-5-yl)(hydroxy)methyl)-2-methylthiophen-3-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate can also be done using TEMPO/NaClO reaction conditions. LCMS: (AA) M+Na 522.6.
To a solution of tert-butyl (1R)-7-chloro-1-[5-(4-chloropyrimidine-5-carbonyl)-2-methyl-3-thienyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (25.0 g, 49.6 mmol) in DMF (50.0 mL, 646 mmol) was added [(1R,2S,4R)-4-amino-2-triisopropylsilyloxy-cyclopentyl]methanol (Int-259, 18.5 g, 64.3 mmol) followed by K2CO3 (17.2 g, 124 mmol) at rt and the reaction was allowed to stir for 5 h. The reaction mixture was concentrated in vacuo to remove DMF. To the residue was added 400 mL of water and the mixture was extracted with EtOAc (400 mL x4). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was subjected to silica gel column chromatography eluting with 80/20 to 50/50 hexane/EtOAc gradient. The byproduct containing fractions were purified by silica gel column chromatography several times. The pure product fractions were combined and concentrated in vacuo to provide 32.6 g (84%) of the title compound as light yellow amorphous solid. This reaction also can be run with bases such as one or more of TEA, DIEA, NMM, and Pyridine. Other solvents can also be used for this transformation such as DMF, THF, DCM, toluene, ethyl acetate, ACN, DME, NMP, dioxane, and DMSO. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.55 (s, 1 H) 8.44 (s, 1 H) 8.21 (d, J=7.53 Hz, 1 H) 7.23 - 7.30 (m, 2 H) 7.13 (s, 1 H) 7.06 (br s, 1 H) 6.33 (s, 1 H) 4.61 - 4.74 (m, 2 H) 4.18 - 4.24 (m, 1 H) 3.95 - 4.03 (m, 1 H) 3.33 - 3.43 (m, 2 H) 3.09 - 3.20 (m, 1 H) 2.78 - 2.86 (m, 2 H) 2.59 (s, 3 H) 2.27 (dt, J=12.92, 8.09 Hz, 1 H) 1.88 - 1.98 (m, 2 H) 1.68 - 1.79 (m, 1 H) 1.41 (s, 9 H) 1.19 - 1.26 (m, 1 H) 0.99 - 1.05 (m, 21 H). LCMS: (AA) M+1 755.3.
To a solution of tert-butyl (1R)-7-chloro-1-[5-[4-[[(1R,3R,4S)-3-(hydroxymethyl)-4-triisopropylsilyloxy-cyclopentyl]amino]pyrimidine-5-carbonyl]-2-methyl-3-thienyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (32.5 g, 41.7 mmol) in DMF (100 mL, 1.29 mol) was added sulfamoyl chloride (10.1 g, 84.5 mmol) at 0 °C with ice/water bath, and the reaction was allowed to stir for 5 min at rt. The reaction was cooled to 0 °C with ice/water bath and quenched by addition of saturated aqueous NaHCO3. The resulting mixture was extracted with EtOAc (x 4). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was dissolved in THF (200 mL) and TBAF-hydrate (17.0 g, 63.7 mmol) was added to the solution at rt. The reaction was then heated to 40 °C and allowed to stir for 2 h. The reaction was quenched by addition of water (500mL) and extracted with EtOAc (x4). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was partially purified by silica gel column chromatography eluting with a 100/0 to 95/5 EtOAc/MeOH gradient. The mixed fractions were purified by silica gel column chromatography eluting with a 99/1 EtOAc/MeOH. The pure fractions were combined and concentrated in vacuo to provide 30.0 g (88%) of the desired compound as light yellow amorphous solid. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.57 (s, 1 H) 8.45 (s, 1 H) 8.17 (d, J=7.53 Hz, 1 H) 7.43 (s, 2 H) 7.23 - 7.31 (m, 2 H) 7.13 (s, 1 H) 7.07 (br s, 1 H) 6.33 (s, 1 H) 4.87 (br d, J=4.52 Hz, 1 H) 4.60 - 4.72 (m, 1 H) 3.88 - 4.11 (m, 4 H) 3.09 - 3.21 (m, 1 H) 2.77 - 2.86 (m, 2 H) 2.59 (s, 3 H) 2.22 - 2.32 (m, 1 H) 2.03 - 2.14 (m, 1 H) 1.87 - 1.96 (m, 1 H) 1.68 - 1.77 (m, 1 H) 1.41 (s, 9 H) 1.22 - 1.30 (m, 1 H). LCMS: (AA) M+1 678.2.
A 2 L round bottom flask was charged with tert-butyl (1R)-7-chloro-1-[5-[4-[[(1R,3S,4R)-3-hydroxy-4-(sulfamoyloxymethyl)cyclopentyl]amino]pyrimidine-5-carbonyl]-2-methyl-3-thienyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (47.4 g, 58.0 mmol) and the content was dissolved in DCM (50.0 mL). The mixture was cooled at 0°C with ice/water bath and then TFA (50.0 mL, 661 mmol) was added to the reaction vessel. The reaction was allowed to stir for 1h at rt. The reaction was diluted with DCM and the mixture was concentrated in vacuo. The residue was azeotroped twice with DCM. The resulting residue was basified by addition of saturated aqueous NaHCO3 and extracted with EtOAc (x4). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was partially purified by silica gel column chromatography eluting with 3% NH4OH: 5% MeOH: 42% DCM: 50% MeCN. The fractions containing the desired product were combined and concentrated in vacuo. The residue was dissolved in a small amount of column eluent and then the solution was divided into four portions. Each portion was purified by silica gel column chromatography eluting with 3% NH4OH: 5% MeOH: 42% DCM: 50% MeCN. Fractions containing desired product were combined and concentrated in vacuo. To the gummy residue was added 200 mL of MeOH followed by slow addition of 1.4L of CH3CN and the resulting solution was allowed to stir slowly at rt for 3 days. The resulting suspension was filtered through a glass fritted funnel and the filter cake was rinsed with CH3CN and then dried in vacuo at 40 °C for 5 days to provide 26.5 g of the title compound. The mother liquor was concentrated in vacuo and the residue was re-purified by silica gel column chromatography eluting with 3% NH4OH: 5% MeOH: 42% DCM: 50% MeCN mixed solution. The pure fractions were combined and concentrated in vacuo. To the residue was added 20 mL of MeOH followed by addition of 500 mL of CH3CN, and the resulting mixture was settled overnight at rt with slow stirring. After filtration of the resulting suspension, the filter cake was dried in a drying oven at 40 °C for 5 days to provide an additional 6.3g of the title compound (total 32.8 g) as I-263a Form 1. 1H NMR (400 MHz, Methanol-d4) δ ppm 8.61 (s, 1 H) 8.52 (s, 1 H) 7.27 (s, 1 H) 7.16 (d, J=1.00 Hz, 2 H) 6.69 - 6.71 (m, 1 H) 5.22 (s, 1 H) 4.70 - 4.82 (m, 1 H) 4.11 - 4.23 (m, 3 H) 3.24 - 3.30 (m, 1 H) 2.96 - 3.12 (m, 2 H) 2.76 - 2.86 (m, 1 H) 2.60 (s, 3 H) 2.43 - 2.53 (m, 1 H) 2.20 - 2.29 (m, 1 H) 2.08 - 2.16 (m, 1 H) 1.87 (dt, J=14.87, 6.87 Hz, 1 H) 1.40 (dt, J=13.05, 9.16 Hz, 1 H). 13C NMR (101 MHz, DMSO-d6) δ 185.40, 160.24, 159.23, 157.75, 146.62, 142.44, 140.41, 138.04, 136.53, 134.47, 131.00, 129.92, 126.11, 126.08, 111.79, 71.29, 70.46, 54.59, 48.74, 45.88, 42.10, 40.58, 33.95, 28.42, 13.82. LCMS: (AA) M-1 576.4. Elemental Anal. Calcd for C25H28ClN5O5S2: C, 51.94; H, 4.88; N, 12.11. Found: C, 51.91; H, 4.81; N, 12.15.
XRPD data is shown in FIG. 2 . XRPD patterns were collected using a Bruker AXS D8 Advance X-ray Diffractometer equipped with LynxEye detector and copper K-alpha (Cu Kα) radiation at 40 kV and 40 mA. A powder sample was gently flattened at the center of a sample holder making smooth surface for diffraction measurement. A 50 mm diameter polymethylmethacrylate sample holder was used. The sample was run as a continuous scan from 2.9° to 29.6° 2θ using 2θ/θ locked coupled angles with step size of 0.025° 2θ and data collection time of 0.4 seconds per step. All data analysis was performed using DIFFRAC.EVA (version 2.1) software (Bruker AXS).
The instruments used for DSC and TGA sample runs were TA Instruments, DSC model Q200 or Q2000, and TGA model Q500 or Q5000.
For DSC, the sample (1 to 2 mg) was sealed in an aluminum pan with pinhole lid. The sample was heated from 25°C to 350°C at a ramp rate of 10°C/min, while the nitrogen sample purge was kept constant at 50 mL/min. Data was collected using Thermal Advantage software for Q Series (version 5.3.5) and data analysis was performed using Universal Analysis 2000 (TA Instruments).
For TGA, the sample (5 to 10 mg) in an open platinum pan was heated from 25°C to 350°C at a ramp rate of 10°C/min with a nitrogen sample purge of 60 mL/min. Data was collected using Thermal Advantage software for Q Series (version 5.3.5) and data analysis was performed using Universal Analysis 2000 (TA Instruments).
Raman spectra were determined using a DXR Raman microscope (Thermo Scientific) equipped with a 780 nm laser. A small amount of sample dispersed on aluminum pan sample holder was observed under Olympus microscope at 10× objective magnifications. Spectra were collected using a 50 µm pinhole aperture in the wave number range of 3500 to 50 cm-1. Spectra analysis was performed using OMINIC 8 software, version 8.3.103 (Thermo Scientific).
DSC data is shown in FIG. 4 ; TGA is shown in FIG. 5 ; and Raman data is shown in FIGS. 6-7 .
The following is an alternative to steps 5 and 6.
To a solution of chlorosulfonyl isocyanate (6.67 g, 47.1 mmol) in acetonitrile (47.1 mL, 901.8 mmol) at 0° C add TBS-silanol (6.50 g, 49 mmol) while maintaining a temperature below 10° C. Stir the mixture at 0-10° C for 30 min; reagent is ready for use as a 1M solution in acetonitrile. The reagent (TBS-chlorosulfonamide) is stable in solution for 24 hours.
Dry solvents and reagents were used and the reaction was carried out under a nitrogen atmosphere. Add pyridine (3.85 g, 48.7 mmol) to a solution of tert-butyl (R)-7-chloro-1-(5-(4-(((1R,3R,4S)-3-(hydroxymethyl)-4-((triisopropylsilyl)oxy)cyclopentyl)amino)pyrimidine-5-carbonyl)-2-methylthiophen-3-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (11.2 g, 15.7 mmol) in NMP (22.4 mL, 233 mmol) at 10° C. Add TBS-chlorosulfonamide (47.1 mL, 47.1 mmol) while maintaining a temp. below 15° C. Monitor reaction for completion via HPLC; reaction reaches completion within 15 min. Quench with sat. aq. sodium bicarbonate (20 mL) and water (50 mL), extract with ethyl acetate (50 mL). Separate organic layer, wash with brine (50 mL), and solvent swap to acetonitrile (30 mL) via distillation. Proceed to deprotection.
Cool the crude tert-butyl (R)-7-chloro-1-(2-methyl-5-(4-(((1R,3R,4S)-3-((sulfamoyloxy)methyl)-4-((triisopropylsilyl)oxy)cyclopentyl)amino)pyrimidine-5-carbonyl)thiophen-3-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (13.1 g, 15.7 mmol) mixture to 10°C. Add phosphoric acid (33.6 mL, 610 mmol) to the reaction mixture while maintaining a temperature below 15°C. The mixture is warmed to ambient temperature. Monitor reaction for completion by HPLC. Reaction reaches full conversion in ∼6 h. Add water (50 mL) and THF (200 mL) to the reaction mixture. Add 15% aqueous sodium carbonate (150 mL) to adjust the pH to 6-7. Vigorous off-gassing occurs during addition - add at an appropriate rate to control off-gassing and foaming. Separate the organic and aqueous phases. Wash the organic phase with brine (50 mL).). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The residue was partially purified by silica gel column chromatography eluting with a 35% 3% NH4OH, 5% MeOH, 42% DCM, 50% MeCN:50% MeCN, 50% DCM to 50% 3% NH4OH, 5% MeOH, 42% DCM, 50% MeCN:50% MeCN, 50% DCM over a gradient. The pure fractions were combined and concentrated in vacuo. The crude ((1R,2S,4R)-4-((5-(4-((R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl)-5-methylthiophene-2-carbonyl)pyrimidin-4-yl)amino)-2-hydroxycyclopentyl)methyl sulfamate is dissolved in premixed 7:1 acetonitrile:methanol solution (90 mL). The mixture is seeded with ((1R,2S,4R)-4-((5-(4-((R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl)-5-methylthiophene-2-carbonyl)pyrimidin-4-yl)amino)-2-hydroxycyclopentyl)methyl sulfamate Form 1 (45 mg, 0.078 mmol). The mixture is stirred for 16h as a slurry develops. Filter the suspension and wash the wet cake twice with MeCN (20 mL, 2X). Dry to constant weight under vacuum at 35°C to provide 4.9 g (54%) of the desired compound as light yellow crystalline solid. 1H NMR (400 MHz, Methanol-d4) δ ppm 8.61 (s, 1 H) 8.52 (s, 1 H) 7.27 (s, 1 H) 7.16 (d, J=1.00 Hz, 2 H) 6.69 - 6.71 (m, 1 H) 5.22 (s, 1 H) 4.70 - 4.82 (m, 1 H) 4.11 - 4.23 (m, 3 H) 3.24 - 3.30 (m, 1 H) 2.96 - 3.12 (m, 2 H) 2.76 - 2.86 (m, 1 H) 2.60 (s, 3 H) 2.43 - 2.53 (m, 1 H) 2.20 - 2.29 (m, 1 H) 2.08 - 2.16 (m, 1 H) 1.87 (dt, J=14.87, 6.87 Hz, 1 H) 1.40 (dt, J=13.05, 9.16 Hz, 1 H). 13C NMR (101 MHz, DMSO-d6) δ 185.40, 160.24, 159.23, 157.75, 146.62, 142.44, 140.41, 138.04, 136.53, 134.47, 131.00, 129.92, 126.11, 126.08, 111.79, 71.29, 70.46, 54.59, 48.74, 45.88, 42.10, 40.58, 33.95, 28.42, 13.82.
To a 50 mm solution of citrate buffer (15 mL, pH = 4.5) was added ((1R,2S,4R)-4-((5-(4-((R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl)-5-methylthiophene-2-carbonyl)pyrimidin-4-yl)amino)-2-hydroxycyclopentyl)methyl sulfamate anhydrous (150 mg, 0.259 mmol) at room temperature. The slurry is mixed for 5 day (shaking or stir bar). Filter the suspension and wash the wet cake twice with water (0.3 mL, 2X). Dry to constant weight under vacuum at 30 °C to provide 51 mg (34%) of the desired compound as light yellow crystal ((1R,2S,4R)-4-((5-(4-((R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl)-5-methylthiophene-2-carbonyl)pyrimidin-4-yl)amino)-2-hydroxycyclopentyl)methyl sulfamate hydrate Form 3.
{(1R,2S,4R)-4-[(5-{[4-(7-chloro-3,4-dihydro-1H-isochromen-1-yl)-5-methyl-2-thienyl]carbonyl}pyrimidin-4-yl)amino]-2-hydroxycyclopentyl}methyl sulfamate (from Example 132, 2.5 g, 4.30 mmol) was dissolved in mixed solution of MeOH (90 mL) and DCM (10 mL). The solution was filtered through a syringe filter and the mixture was settled for 4 days. The mother liquor was then removed by pipet the resulting solid was rinsed with a small amount of MeOH and then dried in vacuo. The solid was transferred to a small vial and further dried in vacuo at 45°C for 10 days to give 1.56g of the title compound as a crystalline solid (needles) (I-257b Form 1). XRPD data is shown in FIG. 1 . DSC data for I-257b Form 1 is shown in FIG. 8 ; TGA is shown in FIG. 9 ; and Raman data is shown in FIGS. 10-11 . Procedures for XRPD pattern collection, DSC, TGA, and Raman spectroscopy were as described above in Example 201. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.61 (s, 1 H) 8.59 (s, 1 H) 8.19 (d, J=7.53 Hz, 1 H) 7.44 (s, 2 H) 7.36 (s, 1 H) 7.22 - 7.30 (m, 2 H) 6.75 (s, 1 H) 5.91 (s, 1 H) 4.88 (d, J=4.52 Hz, 1 H) 4.69 (sxt, J=8.08 Hz, 1 H) 4.05 - 4.17 (m, 2 H) 3.91 - 4.01 (m, 2 H) 3.78 - 3.88 (m, 1 H) 2.95 - 3.09 (m, 1 H) 2.77 (br d, J=16.69 Hz, 1 H) 2.48 (s, 3 H) 2.26 - 2.37 (m, 1 H) 2.06 - 2.17 (m, 1 H) 1.90 - 1.99 (m, 1 H) 1.70 - 1.80 (m, 1 H) 1.27 (dt, J=12.67, 9.29 Hz, 1 H). LCMS: (FA) M+1 579.1.
To a solution of [(1R,2S,4R)-4-{[5-({4-[(1R)-3,4-Dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate (86% de, 987 mg, from Example 131) in CH2Cl2 (40.0 mL) was slowly added hexanes (25.0 mL) to give a white suspension. To the suspension was added CH2Cl2 dropwise until the suspension once again became a clear solution (10.0 mL). After stirring for 19 hours at room temperature, the precipitated solid was collected by filtration, washed with small amount of CH2Cl2 and Et2O and dried in vacuo at 45 °C to afford 799 mg of a light yellow solid as I-256b Form 1. XRPD data is shown in FIG. 3 . DSC data is shown in FIG. 12 and TGA is shown in FIG. 13 . Procedures for XRPD pattern collection, DSC, and TGA were as described above in Example 201. The diastereomeric purity of I-256b was determined to be 92.7% de by HPLC (70/30/0.1 hexane/EtOH/DEA; 1.0 mL/min for 60 min; using a CHIRALPAK IC column (4.6 × 250 mm)): 23.3 min (minor diastereomer) and 32.1 min (major diastereomer, I-256b).
In certain instances described in the preceding examples and tables, mixtures of diastereomers were generated and subsequently separated into the individual component diastereomers. Where applicable, the preparative scale chiral chromatography conditions (HPLC or SFC) employed for the separation of the diastereomers are listed in the table below. The table below also details the chiral chromatography conditions (HPLC or SFC) that were used to analyze the diastereomeric purity of the resulting compounds as well as the retention times for each of the compounds listed.
| I-257 | SFC: 35% [0.3% DEA in MEOH ]/65% CO2 on IA (10X250mm; 5 micron) at 10 mL/min FR ; BPR = 15MPa | SFC: 40% [0.3% DEA in MEOH ]/60% CO2 on IA (4.6X100mm; 5 micron) at 4 mL/min FR; 5 min; BPR = 10MPa | |
| 1-256 | SFC: 40% [0.3% FA in MEOH ]/60% CO2 on IF (10X250mm; 5 micron) at 10 mL/min FR ; BPR = 15MPa | SFC: 40% [0.3% FA in MEOH ]/60% CO2 on IF (4.6X100mm; 5 micron) at 4 mL/min FR; 5 min; BPR = 10MPa | |
| SFC: 30% [0.3% DEA in EtOH ]/70% CO2 on IA (4.6X100mm; 5 micron) at 4 mL/min FR; 10 min; BPR = 10MPa | |||
The table below describes the 1H NMR and LC/MS data for compounds prepared herein.
| I-257 | ||
| I-257b | ||
| 1-256 | ||
| I-256a | ||
| I-256b | ||
| I-263a | ||
| I-263b | ||
| I-257a |
The SAE enzymatic reaction totals 50 µl and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 5 mM MgCl2, 0.5 µM ATP, 250 µM GSH, 0.01 µM Ubc9-GST, 0.125 µM Sumo-Flag and 0.11 nM recombinant human SAE enzyme. The enzymatic reaction mixture, with and without inhibitor, Is incubated at 24°C for 105 min in a 384-well plate before termination with 25 µM of Stop/Detection buffer (0.1M HEPES Hemisodium pH 7.5, 0.05% Tween20, 20 mM EDTA, 410 mM KF, 0.53 nM Europium-Cryptate labeled monoclonal anti-Flag M2 Antibody (CisBio International) and 8.125 µg/ml PHYCOLINK goat anti-GST allophycocyanin (XL-APC) antibody (Prozyme)). After incubation for 2 hours at 24°C, quantification of FRET is performed on the Pherostar™ (BMG Labtech). Percentage inhibition values at a single concentration or enzyme inhibition (IC50) values are determined from those curves. One skilled in the art will appreciate that the values generated either as percentage inhibition at a single concentration or IC50 values are subject to experimental variation.
The cell viability assay is used to measure the effect of various compounds on cancer cell proliferation. Promega's CellTiter-Glo® Luminescent Cell Viability Assay is used to measure ATP concentration present in all metabolically active cells and the concentration declines rapidly when cells undergo necrosis or apoptosis.
The cancer cell lines of interest are propagated in recommended growth medium (Invitrogen) containing 10% Fetal Bovine Serum (Hyclone or ATCC) and 100 I.U.Penicellin/100 µg/mL Streptomycin (Invitrogen) and kept in tissue culture incubator at 37°C with 5% CO2. On day 1, attached cells are trypsinized with 4.5 mL of 0.25% Trypsin-EDTA (Invitrogen) at 37°C for 2 minutes or until cells have detached. Suspension cells are collected and washed. Desired number of cells are cultured in 25 µL of media per well in tissue culture-treated black-walled, clear bottom 384-well plates (BD Biosciences) for 16-24 hours. The exact number of cells per well are optimized for each individual cell line. On day 2, 62.5 nL test compounds in DMSO (ranging from 10 mM to 508 uM in 10 point 3-fold dilution series) are directly added to cells in 384-well plate using Echo liquid handler (Labcyte). This results in a final concentration range of 0.0013 to 25 µM in 3-fold dilutions in the cell plates. On day 5 after 72 hour of incubation in tissue culture incubator, 25 µL CellTiter-Glo®(Promega) are added to the compound treated cell plates. The cell plates are incubated at room temperature for 15 min and then read luminescence on Pherastar plate reader (BMG). The test compound concentration versus cell viability curves are generated using percentage of survival calculated from luminescence readout relative to DMSO and media only controls. The percentage growth inhibition values at a single concentration (LD50) values are determined from the curves.
SAE inhibitors are tested for their ability to inhibit tumor growth in standard xenograft tumor models. For example, HCT-116 cells (1×106) in 100 µL of phosphate buffered saline are aseptically injected into the subcutaneous space in the right dorsal flank of female CD-1 nude mice (age 5-8 weeks, Charles River) using a 23-ga needle. Beginning at day 7 after inoculation, tumors are measured twice weekly using a vernier caliper. Tumor volumes are calculated using standard procedures (0.5 × length × width2). When the tumors reach a volume of approximately 200 mm3, mice are randomized by tumor volume into treatment groups and injected subcutaneously with test compound (300 µL) at various doses and schedules. All control groups receive vehicle alone. Tumor size and body weight are measured twice a week, and the study is terminated when the control tumors reach approximately 2000 mm3. Analogous procedures are followed for colon (colo205 or HCT-116 cells), AML (THP-1 or HL-60 cells), DLBCL (Ly10 or WSU-DLCL2), melanoma (A375 or A2058 cells) and lung (H460 cells) tumor models.
As detailed above, chemical entities of the disclosure inhibit SAE. In certain embodiments, chemical entities of the disclosure inhibit SAE with the percent inhibition at the concentrations shown in the table below. In certain embodiments, chemical entities of the disclosure inhibit SAE with the IC50 values shown in the table below.
| 1-256 | 0.111 | 100 | A |
| I-256a | 0.111 | 94 | A |
| I-256b | 0.111 | 99 | A |
| I-257a | 0.111 | 74 | B |
| I-257b | 0.111 | 99 | A |
| I-263a | 0.111 | 101 | A |
| I-263b | 0.111 | 89 | B |
Claims (15)
- A chemical entity chosen from: and pharmaceutically acceptable salts thereof.
- The chemical entity of claim 1, wherein the chemical entity is chosen from:
[(1R,2S,4R)-4-{[5-({4-[(1S)-3,4-dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate; and I-256 [(1R,2S,4R)-4-{[5-({4-[(1R)-3,4-Dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate; I-256a [(1R,2S,4R)-4-{[5-({4-[(1S)-3,4-dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate; I-256b [(1R,2S,4R)-4-{[5-({4-[(1R)-3,4-dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate; - The chemical entity of claim 2, wherein the chemical entity is chosen from: [(1R,2S,4R)-4-{[5-({4-[(1R)-3,4-Dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate of formula I-256b and pharmaceutically acceptable salts thereof.
- The chemical entity of claim 3, wherein the chemical entity is crystalline Form 1 of: [(1R,2S,4R)-4-{[5-({4-[(1R)-3,4-Dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate of formula I-256b, wherein Form 1 is characterized by an X-ray powder diffraction peak at 2θ angle of 21.1°.
- The chemical entity of claim 1, wherein the chemical entity is chosen from:
I-257 [(1R,2S,4R)-4-{[5-({4-[(1S)-7-Chloro-3,4-dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate; and [(1R,2S,4R)-4-{[5-({4-[(1R)-7-Chloro-3,4-dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate; I-257a [(1R,2S,4R)-4-{[5-({4-[(1S)-7-Chloro-3,4-dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate; I-257b [(1R,2S,4R)-4-{[5-({4-[(1R)-7-Chloro-3,4-dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate; - The chemical entity of claim 5, wherein the chemical entity is chosen from: [(1R,2S,4R)-4-{[5-({4-[(1R)-7-Chloro-3,4-dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate of formula I-257b and pharmaceutically acceptable salts thereof.
- The chemical entity of claim 6, wherein the chemical entity is crystalline Form 1 of: [(1R,2S,4R)-4-{[5-({4-[(1R)-7-Chloro-3,4-dihydro-1H-isochromen-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate of formula I-257b; wherein Form 1 is characterized by an X-ray powder diffraction peak at 2θ angle of 25.2°.
- The chemical entity of claim 1, wherein the chemical entity is chosen from:
I-263a [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate; I-263b [(1R,2S,4R)-4-{[5-({4-[(1S)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate; - The chemical entity of claim 8, wherein the chemical entity is chosen from: [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate of formula I-263a and pharmaceutically acceptable salts thereof.
- The chemical entity of claim 9, wherein the chemical entity is crystalline Form 1 of: [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate of formula I-263a; wherein Form 1 is characterized by an X-ray powder diffraction peak at 2θ angle of 21.6°.
- The chemical entity of claim 9, wherein the chemical entity is crystalline Form 2 of: [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate of formula I-263a; wherein Form 2 is characterized by an X-ray powder diffraction peak at 2θ angle of 19.0.
- The chemical entity of claim 9, wherein the chemical entity is crystalline Form 3 of: [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate of formula I-263a; wherein Form 3 is characterized by an X-ray powder diffraction peak at 2θ angle of 15.6°.
- The chemical entity of claim 8, wherein the chemical entity is chosen from: [(1R,2S,4R)-4-{[5-({4-[(1S)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate of formula I-263b and pharmaceutically acceptable salts thereof.
- A pharmaceutical composition comprising the chemical entity of any one of claims 1 to 13 and a pharmaceutically acceptable carrier.
- The chemical entity of any one of claims 1 to 13 or the pharmaceutical composition of claim 14, for use in treating cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462019756P | 2014-07-01 | ||
| US201562185678P | 2015-06-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HK1237266A1 HK1237266A1 (en) | 2018-04-13 |
| HK1237266B true HK1237266B (en) | 2020-07-17 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3164130B1 (en) | Heteroaryl compounds useful as inhibitors of sumo activating enzyme | |
| TWI894229B (en) | Biaryl derivatives as yap/taz-tead protein-protein interaction inhibitors | |
| US9969716B2 (en) | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof | |
| EP2555768B1 (en) | Ire-1 inhibitors | |
| CA2916468C (en) | Heteroaryl compounds useful as inhibitors of sumo activating enzyme | |
| JP2016199604A (en) | Nuclear transport regulators and uses thereof | |
| CN108137507A (en) | Proteolysis conditioning agent and relevant application method based on MDM2 | |
| WO2009134850A1 (en) | Prolyl hydroxylase inhibitors | |
| JP2022535577A (en) | Imidazo[1,2-C]pyrimidine derivatives as PRC2 inhibitors for treating cancer | |
| US20250195475A1 (en) | Cdk2 inhibitor and preparation method and use thereof | |
| JP2022530866A (en) | Diazanaphthalene derivative as a PRC2 inhibitor | |
| CN111484491A (en) | Substituted pyrido-cyclic compounds, process for their preparation and their use | |
| CN115043836B (en) | P2X3 receptor selective modulator of imidazopyridine derivative and pharmaceutical application thereof | |
| CN116783183A (en) | 1-(2-(4-Cyclopropyl-1H-1,2,3-triazol-1-yl)acetyl)-4-hydroxy-N-(benzyl) as a VHL inhibitor for the treatment of anemia and cancer pyrrolidine-2-carboxamide derivatives | |
| HK1237266B (en) | Heteroaryl compounds useful as inhibitors of sumo activating enzyme | |
| HK1237266A1 (en) | Heteroaryl compounds useful as inhibitors of sumo activating enzyme | |
| CN118434743A (en) | Tricyclic heterocycles | |
| WO2009134847A1 (en) | Prolyl hydroxylase inhibitors | |
| WO2010059555A1 (en) | Prolyl hydroxylase inhibitors | |
| CA3222543A1 (en) | Use of substituted 5-(4-methyl-6-phenyl-4h-benzo[f]imidazo[1,5-a][1,4] diazepin-3-yl)-1,2,4-oxadiazoles in the treatment of inflammatory conditions | |
| HK1179171B (en) | Ire-1 inhibitors | |
| HK1179171A (en) | Ire-1 inhibitors |